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“The only weapon with which the unconscious 
patient can immediately retaliate upon the 
incompetent surgeon is haemorrhage” 
William Halsted  
(Bulletin of the John Hopkins Hospital 1912; 23: 191) 
 
 
 
 
 
  
 ABSTRACT 
Background: Perioperative bleeding complications are associated with 
increased morbidity and mortality. One way to minimize perioperative 
bleeding and transfusion is to identify patients at risk of bleeding. 
Preoperative fibrinogen plasma concentration and factor XIII (FXIII) activity 
may be indicators of perioperative bleeding and transfusion. The aim of the 
thesis was to investigate 1) whether there is a correlation between the levels 
of preoperative coagulation factors and perioperative bleeding and 
transfusion in elective orthopaedic surgery patients, 2) transfusion and blood 
loss in arthroplasty surgery and possible risk factors, and 3) the ability of 
FXIII to improve clot formation in blood samples from cardiac and scoliosis 
surgery patients. 
Patients and methods: The study described in Paper I, involved 82 patients 
undergoing idiopathic scoliosis surgery. Preoperative fibrinogen plasma 
concentration was correlated with perioperative bleeding and red blood cell 
(RBC) transfusion requirements. The studies described in Papers II and III 
involved 245 patients undergoing either degenerative spine fusion surgery 
(52), elective total unilateral primary hip arthroplasty (THA) (114), or knee 
arthroplasty (TKA) (79). In Paper II perioperative bleeding and transfusion 
requirement in THA and TKA patients were investigated. In Paper III 
preoperative fibrinogen plasma concentration and FXIII activity were 
correlated with perioperative bleeding and RBC transfusion in the three 
surgery groups. In Paper IV, blood samples from patients undergoing 
cardiac surgery (9) and scoliosis surgery (10) were supplemented with three 
increasing doses of FXIII concentrate, alone or in combination with a fixed 
dose of either fibrinogen concentrate or fresh apheresis platelets. Clot 
formation was assessed with modified rotational thromboelastometry 
(ROTEM®).  
Results: An association was found between low fibrinogen concentration and 
large perioperative bleeding and RBC transfusion for scoliosis surgery 
patients (Paper I). An association was found between low fibrinogen and 
large perioperative bleeding in spine surgery, but not in THA or TKA 
patients (Paper III). No association was observed between fibrinogen and 
RBC transfusion or between FXIII activity and perioperative bleeding and/or 
RBC transfusion in any of the surgery groups. A lower prevalence of red 
blood cell transfusion in THA and TKA than previously reported was found 
(Paper II). Low preoperative hemoglobin levels, low body mass index and 
long operation time increased the risk for RBC transfusion. In Paper IV 
EXTEM clotting time was shortened and FIBTEM maximum clot firmness 
was increased compared to baseline in both surgery groups when FXIII was 
added. The effect was more pronounced when fibrinogen concentrate or 
platelets were added. 
Conclusions: Preoperative measurement of fibrinogen plasma concentration, 
but not preoperative FXIII activity, may be useful to identify patients at risk 
of perioperative bleeding and transfusion in certain types of elective 
orthopaedic surgery. In THA and TKA patients, RBC transfusions are 
relatively rarely given today. Risk factors for large bleeding and red blood 
cell transfusion in unselected elective THA or TKA patients are low 
preoperative hemoglobin levels, low body mass index and long operation 
time. Ex vivo supplementation with clinically relevant doses of FXIII dose-
dependently improve clot formation in blood samples from cardiac surgery 
and idiopathic scoliosis surgery patients, both alone and when given in 
combination with fibrinogen or platelets.  
 
Keywords: orthopaedic surgery, fibrinogen, factor XIII, surgical bleeding, 
transfusion 
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 SAMMANFATTNING PÅ SVENSKA 
Bakgrund: Blödningskomplikationer i samband med kirurgi är förenade med 
ökad sjuklighet och dödlighet. Ett sätt att minimera blödning och 
blodtransfusioner är att identifiera patienter med risk för blödning under och 
efter operation. Mätning av koagulationsfaktorerna fibrinogen och faktor XIII 
(FXIII) innan operation har föreslagits kunna ge information om vilka 
patienter som har ökad risk för större blödning under kirurgi och om det finns 
risk för behov av blodtransfusion. Studierna i denna avhandling undersöker 
om det finns ett samband mellan fibrinogen och FXIII, och blödning och 
blodtransfusion vid planerad ortopedisk kirurgi. Vidare undersöks blödning 
och transfusionsbehov, samt riskfaktorer för dessa, vid planerad höft- och 
knäproteskirurgi. I en experimentell studie studeras effekten av FXIII på 
koagulationsförmågan i blodprover från patienter som genomgått hjärt- och 
skolioskirurgi. 
Patienter och metoder: I artikel I redovisas en studie som inkluderade 82 
unga patienter som opererades på grund av skolios. Patienternas 
fibrinogennivåer före operationen jämfördes med blödning under och efter 
kirurgin, samt med behovet av blodtransfusion under vårdtiden. I artikel II 
och III, studerades 245 patienter som genomgick antingen steloperation i 
ryggen (n=52), ensidig höftproteskirurgi (n=114), eller knäproteskirurgi 
(n=79). I artikel II undersöktes blödning under kirurgi och behovet av 
blodtransfusion under vårdtiden samt riskfaktorer för dessa. I artikel III 
jämfördes patienternas nivåer av fibrinogen och FXIII före operationen med 
blödning under och efter kirurgi, samt med behovet av blodtransfusion under 
vårdtiden, hos de tre patientgrupperna. I artikel IV togs blodprover från nio 
patienter som genomgick hjärtkirurgi och tio patienter som genomgick 
skolioskirurgi. I blodproverna tillsattes tre olika doser av FXIII-koncentrat, 
ensamt eller i kombination med en fast dos av antingen fibrinogen-koncentrat 
eller färska blodplättar (trombocyter). Blodets koagulationsförmåga 
bedömdes med metoden modifierad rotationstromboelastometri (ROTEM®). 
Resultat: Hos unga skoliospatienter (artikel I) sågs ett samband mellan låga 
nivåer av fibrinogen före operation och större blödning under och efter 
kirurgi, samt med större behov av blodtransfusion under vårdtiden. I artikel 
III sågs ett samband mellan låga fibrinogennivåer före operation och större 
blödning hos ryggkirurgiska patienter som genomgick steloperation. Detta 
samband sågs ej vid höft- eller knäproteskirurgi. Inget samband mellan 
fibrinogennivåer och behovet av blodtransfusion, eller mellan FXIII-aktivitet 
och blödning eller behov av blodtransfusion, kunde påvisas i någon av 
patientgrupperna. I artikel II sågs en lägre förekomst av blodtransfusion vid 
höft- och knäproteskirurgi än vad som tidigare rapporterats. Lågt blodvärde 
före operationen, lågt body mass index (BMI) och lång operationstid ökade 
risken för blodtransfusion. I artikel IV förbättrades blodets 
koagulationsförmåga när FXIII tillsattes, ensamt eller i kombination med 
fibrinogen-koncentrat eller blodplättar, mätt med ROTEM®, både i blod från 
hjärt- och från skoliospatienter.  
Slutsatser: Fibrinogen-koncentration uppmätt före operation kan identifiera 
patienter med ökad risk för blödning och behov av blodtransfusioner under 
och efter operationen vid vissa typer av planerad ortopedisk kirurgi. Däremot 
är mätning av FXIII-aktivitet före planerad ortopedisk kirurgi inte till hjälp 
för att identifiera riskpatienter avseende blödning och/eller blodtransfusion. 
Antalet patienter som erhåller blodtransfusion vid total höft- och 
knäledsproteskirurgi är idag lägre än vad som tidigare rapporterats. 
Riskfaktorer för stor blödning och blodtransfusion är lågt blodvärde före 
operationen, lågt BMI och lång operationstid. 
Vid tillsatts av rimliga behandlingsdoser av FXIII-koncentrat till blodprover 
från patienter som genomgår hjärtkirurgi eller skolioskirurgi, kan blodets 
koagulationsförmåga förbättras. Detta gäller både när FXIII-koncentrat ges 
ensamt och när det ges i kombination med fibrinogen-koncentrat eller 
blodplättar. 
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1 INTRODUCTION 
Major perioperative bleeding, defined as bleeding during and in relation to 
the surgical procedure, increases morbidity and mortality. In order to ensure 
safe and efficient surgical procedures it is important to minimize bleeding 
and the subsequent need for transfusions but also to optimize the patient’s 
coagulation competence. [204] 
Some types of open orthopaedic surgery are associated with large 
perioperative blood loss and, as a consequence, frequent use of allogeneic 
transfusion of blood products. Various measures can be taken, pre-, intra, and 
postoperatively, to reduce bleeding and the need for transfusions; treatment 
of preoperative anemia, autologous blood transfusion programs, cell saving 
techniques, hemostatic drugs, transfusion guidelines and protocols. [22, 204] 
All these measures are based on knowledge on what increases the risk of 
large perioperative bleeding and for transfusion, Figure 1.  
This thesis was initiated based on findings in other surgical patient groups. 
Preoperative measurements of coagulation factors, such as fibrinogen and 
coagulation factor XIII, have been found to be of importance to minimize 
perioperative bleeding and transfusion requirements. [50, 116] To investigate 
this in an orthopaedic surgery setting, studies in patient groups historically 
known to require transfusions, such as arthroplasty patients and patients 
undergoing spine surgery procedures, were designed and performed. Due to 
the many changes in the routines of today a separate study of bleeding and 
transfusion rates in arthroplasty patients was additionally performed. 
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Figure 1. Factors influencing bleeding and transfusion requirements in the 
surgical setting.  
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1.1 Bleeding and transfusion in surgery 
Bleeding in surgery is inevitable. In order to take the right measures to 
minimize bleeding it is important to know what factors influence 
perioperative bleeding.  
The International Society on Thrombosis and Haemostasis (ISTH, 
www.isth.org) has defined major bleeding in surgical patients. [198] 
Simplified, this definition states that a major bleeding can be a fatal bleeding, 
bleeding that is symptomatic and occurs in a critical area or organ or surgical 
site bleeding that requires a secondary intervention. It can also be a bleeding 
that causes a drop in hemoglobin (Hb) level by 20 g/L or where the patient 
receives at least two units of red blood cell (RBC) transfusion. 
Another definition by the Swedish Society on Thrombosis and Haemostasis 
(SSTH, www.ssth.se) for massive bleeding is a bleeding requiring transfusion 
of >10 units of RBC in the previous 24 hours. [23]  
Ginzburg and Dujardin studied orthopaedic surgeons’ definition of major 
bleeding in 2011. [75] The study showed that surgeons were more concerned 
about bleeding that caused re-operation than bleeding that caused a drop in 
Hb level. Transfusion of >2 units of RBC was considered a relevant threshold 
for major bleeding. 
 
1.1.1 Surgical factors 
Operation time has been shown to affect perioperative bleeding in 
orthopaedic and cardiac surgery. [144, 169] However, the cause and effect is 
difficult to establish. During major orthopaedic surgical procedures there is a 
continuous bleeding from exposed bone marrow and cancellous bone 
surfaces. Operation time can be increased because of bleeding that obscures 
the surgery field.  
The type of anesthesia affects perioperative bleeding and transfusion in total 
hip arthroplasty (THA) and total knee arthroplasty (TKA) surgery. [102, 120, 
154, 189] Regional anesthesia, most commonly spinal anesthesia, lowers the 
mean arterial blood pressure and affects the venous return. [161] This gives a 
lower perfusion pressure in the surgical field with subsequent lower blood 
loss. 
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In surgery of the limbs it is easy to minimize intraoperative blood loss by 
using a tourniquet. Studies on TKA surgery have shown differing results on 
perioperative bleeding; some studies show lower perioperative bleeding in 
patients operated in a bloodless field while other studies show no difference. 
[5, 12, 109, 137] One study by Tetro and Rudan in 2001 even showed a 
higher perioperative blood loss in the tourniquet group. [228] The same study 
showed no difference in transfusion requirements between the groups.  
The experience of the surgeon might also influence the perioperative 
bleeding. [251] This relationship is also difficult to establish because of 
confounding factors. 
 
1.1.2 Patient related factors 
Anemia is one of the major patient-related risk factors for transfusion during 
surgery. [9, 18, 30, 82, 92, 144, 157] A low Hb level affects blood 
coagulation, described in Section 1.2.2. During surgery the patients with an 
initial low Hb levels reaches critically low Hb faster because of the bleeding 
and hemodilution during surgery.  
The main function of RBC is to deliver oxygen to the tissues. The body has 
several mechanisms to optimize this delivery, including respiratory and 
cardiac adaption as well as increased tissue oxygen extraction in anemia. 
[205] An Hb concentration of 130 g/L in men, and 120 g/L in women is 
defined as clinical anemia according to the WHO. [2] Anemia can have a 
number of causes, such as lack of production of RBCs, destruction of RBCs, 
or acute or chronic bleeding. [79] Women, on average, have a lower Hb 
concentration and a smaller blood volume. 
Studies show that obese patients bleed more during elective orthopaedic 
surgery. [32, 88, 110] At the same time surgery in obese patients takes 
longer, and a long operation time has been shown to increase bleeding. To 
complicate the matter further, a study in cardiac surgery patients shows an 
increased risk for reexploration for bleeding in patients with low body mass 
index (BMI). [118] 
Other suggested patient-related risk factors for perioperative bleeding and 
transfusion are high age and gender. [18, 118, 174, 182] Studies differ, 
however, and the causality between gender and bleeding is not clear.  
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1.2 Coagulation 
The coagulation system is complex and allows for controlled coagulation at 
the site of injury without the clot spreading throughout the vascular tree.  
Blood coagulation interacts with many other bodily systems such as the 
inflammatory system and angiogenesis, as well as medications, infectious 
agents and foreign materials. The following section provides an overview of 
blood coagulation and clinically important factors affecting blood 
coagulation.  
 
1.2.1 The coagulation cascade 
Knowledge about the ability of the blood to form clots has been known since 
ancient times. In the 19th century, scientists began to learn more about the 
different factors that lay behind the thrombus formation. [195, 237] 
Because of the plethora of names used for the different factors in the early 
days of coagulation research, an International Committee for the 
Standardization of the Nomenclature of Blood Clotting Factors was 
established at the International Congress of Thrombosis and Embolism in 
Basel in 1954. Coagulation factors were given a Roman numeral in the order 
they were discovered. The first four factors were already known by their 
names so are not referred to by their standardized number. [246, 247] 
Coagulation factor XIII was the last factor to be given a roman numeral. 
Today the committee is called the Scientific and Standardization Committee 
(SSC) and is part of ISTH. 
Table 1. Coagulation factors 
Factor Synonym Factor Synonym 
I Fibrinogen VIII Antihemophilic globulin 
II Prothrombin IX Christmas factor 
III Thromboplastin, Tissue factor X Stuart-Prower factor 
IV Calcium, Ca2+ XI Plasma thromboplastin antecedent 
V Proaccelerin XII Hageman factor 
VI Same as factor V XIII Fibrin stabilizing factor 
VII Proconvertin   
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Figure 2. Schematic overview of the coagulation cascade. ADP = Adenosine 
diphosphate, TF = Tissue factor, vWF = von Willebrand factor, APC = 
Apoprotein C, PS = Protein S, TM = Thrombomodulin, AT = Antithrombin, FVa 
= activated Factor V, FVIIa = activated Factor VII, FVIIIa = activated Factor 
VIII, FIXa = activated Factor IX, FXa = activated Factor X, FXIa = activated 
Factor XI 
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Primary hemostasis 
The coagulation cascade was previously divided into the intrinsic, platelet 
derived pathway, and the extrinsic, plasma coagulation factor-driven 
pathway. Even if this categorization is still in use, for instance when defining 
coagulation assays, a more explanatory way of describing the coagulation 
cascade is by dividing it into primary and secondary hemostasis. [15] 
The endothelial cells in the blood vessel wall are designed so that they do not 
spontaneously initiate the coagulation cascade. The negatively charged 
platelets are repelled by an equally negatively charged glycocalyx on the 
endothelial cells. The endothelial cells produce a small amount of 
endogenous heparin that together with circulating antithrombin inactivates 
coagulation factors.  
When a blood vessel injury occurs, the vessel constricts as a response to the 
injury. The antithrombotic glycocalyx is removed at the injury site and the 
platelets are not repelled but, instead, are pushed towards the vessel wall by 
fluid dynamics. Subendothelial collagen is exposed and the platelets are 
activated. The platelets are also activated by circulating thrombin and 
adenosine diphosphate (ADP). Von Willebrand factor (vWF) secures the 
platelets to the vessel wall. The platelets then change form and become 
irregular and form pseudopods, thereby increasing their surface area, on 
which platelet procoagulant receptors are exposed. The activated platelets 
form a monolayer over the injury and the coagulation cascade proliferates on 
the surface.  
The activated platelet releases ADP, Ca2+, serotonin, vWF, factor V, factor 
XIII and fibrinogen, all substances that help the continuing thrombus 
formation. 
 
Secondary hemostasis 
Injury to the endothelial cells exposes thromboplastin, also called tissue 
factor (TF). Tissue factor activates factor VII and, together, they form a 
complex that in turns activates factor V and factor X, which also form a 
complex at the site of injury. This FVa/FXa complex is called 
prothrombinase and it activates prothrombin into thrombin. 
Thrombin is a strong procoagulant factor and its main role is to activate 
fibrinogen into fibrin, which forms the fibrin clot. It also activates platelets 
and other coagulation factors. Only a small amount of thrombin is needed to 
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initiate coagulation on the surface of the vessel wall. In the next step, the 
propagation phase, hemostasis takes place on the activated platelets covering 
the injury. 
The thrombin burst, where a large amount of thrombin is activated, and the 
amplified activation of coagulation factors, is due to enlarged surface of the 
activated platelets and the large amount of procoagulants expressed on that 
surface. The coagulation factors link with the surface through Ca2+ bonds. 
The large amount of thrombin can, in turn, convert large amounts of 
fibrinogen into fibrin, which forms the fibrin clot. Thrombin also activates 
FXIII, which stabilizes the clot by forming crosslinks with fibrin. 
The surplus of activated factors is released to plasma and is inactivated by 
antithrombin. The anticoagulant properties of the uninjured vessel walls limit 
coagulation to the site of injury. For instance, circulating thrombin attaches to 
thrombomodulin on the vessel wall. This complex activates protein C and 
protein S which inactivates FV and FVIII and stops their activation of 
thrombin. 
 
1.2.2 What affects coagulation? 
Many of the coagulation factors have catalytic functions in the coagulation 
cascade, and 30% of normal plasma concentration of these factors is assumed 
to be sufficient to maintain coagulation. Others, like fibrinogen, FXIII and 
platelets are consumed during coagulation and sufficient levels are critical for 
clotting. [15] 
 
Patient related factors 
The most obvious patient-related factors are different types of bleeding 
disorders. The most common bleeding disorders are hemophilia A and B and 
von Willebrand disease, all of which are congenital. In 2012, the prevalence 
of hemophilia A was 7.1 per 100,000 inhabitants, for hemophilia B 1.7 per 
100,000 inhabitants, and for von Willebrand disease one in 100 inhabitants. 
[16, 221]  
Platelet dysfunction and thrombocytopenia also affect coagulation. 
Congenital platelet dysfunctions are rare and diverse. [113] Examples are 
Bernard-Soulier syndrome, which affects platelet adhesion to the vessel 
walls, and Glanzmann thrombasteni, which affects platelet binding with 
Malin S Carling 
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fibrinogen. Various conditions that affect bone marrow generation and 
increase consumption of platelets, such as myelodysplastic syndromes, large 
alcohol consumption or drug-induced thrombocytopenia, cause 
thrombocytopenia.  
In the blood vessel, platelets migrate towards the vessel wall because of 
hemodynamic and rheological factors. Hemoglobin levels influence this 
migration, and anemic patients may not have enough red blood cells to push 
the platelets to the vessel wall, thereby lowering the actual platelet count at 
the site of injury. [4] The hemoglobin concentration at which coagulation is 
affected is unclear. [131] 
Blood coagulation is also temperature dependent. Even small changes in core 
temperature (<1°C) increase perioperative blood loss and increases 
transfusion rates. [187] However, studies are not conclusive and body 
temperature should be seen as just one of many ways to optimize the 
patient’s coagulation system. [52, 131] 
In vitro studies suggest that coagulation is pH dependent as well. The TF-
factor VII-complex has diminished activity in an acidotic environment. [156] 
The combination of low pH and low body temperature is even more 
detrimental to coagulation. Patients with large bleeding due to trauma are 
often cold because of the circumstances during and after trauma, and this is 
often combined with acidosis. In these cases it is important to reverse the low 
body temperature and acidosis to optimize coagulation before necessary 
surgery is carried out. [99] 
Calcium is an important part of the coagulation cascade. A plasma 
concentration of 0.9 mmol/L appears to be required to ensure coagulation. 
[54] In trauma patients it has been shown that hypocalcemia on admission to 
hospital was associated with increased mortality and a larger risk of massive 
transfusion. Hypocalcemia may also be the result of massive transfusion 
since citrate, used in fresh frozen plasma (FFP) and platelet transfusion as an 
anticoagulant, binds Ca2+. [216] 
Diet and other lifestyle factors may also have an impact on hemostasis. [138, 
180] This has been widely studied in terms of relation to cardiovascular 
disease, but not much is known about how this affects bleeding and 
transfusion in a surgical setting. Fish oil, as a dietary supplementation to 
prevent atherosclerotic disease, has been studied, but no effect on bleeding or 
transfusion rates has been demonstrated. [239]  
Aspects on bleeding and transfusion in elective orthopaedic surgery 
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High alcohol consumption can cause thrombocytopenia and liver cirrhosis. 
Thrombocytopenia in persons with high alcohol consumption both reduces 
the number of platelets and affects platelet aggregation. [94] Many pro- and 
anticoagulant factors are produced in the liver, so liver cirrhosis, not only on 
the basis of alcohol, can cause both bleeding and thrombotic disorders. Even 
if these patients have a high prothrombin time (PT) they should not be given 
procoagulants such as prothrombin complex concentrates (PCC) and, in 
conditions with increased risk of thrombotic events, such as surgery or 
immobilization, thrombosis prophylaxis should always be considered. [131, 
143] 
 
Iatrogenic factors 
Different drugs affect the coagulation system. Some are supposed to down-
regulate the coagulation cascade by inhibiting coagulation factors or the 
platelets, while others have this as a side effect. This can cause difficulties if 
a patient on these medications requires acute or planned surgery or if the 
patient is subjected to major trauma. 
The discovery of heparin in 1916 and the development of low molecular 
weight heparin (LMWH) were milestones in medicine. Heparin allows 
physicians to treat hypercoagulant and thrombotic diseases and it is also used 
to prevent thromboembolism in, for example, patients undergoing surgery 
and in atrial fibrillation.  
Because LMWH are administered as subcutaneous injections, warfarin is 
preferred for long-term treatment. The disadvantages of warfarin are that it 
must be monitored regularly and that the drug interacts with other 
medications as well as different types of food. New oral anticoagulants 
(NOAC) have been developed that allow safe anticoagulation without 
monitoring. [199] Because NOACs have not been in use for long; the first 
NOAC still in use, dabigatran, was released in Sweden in 2008. 
Consequently, studies are needed of NOACs in combination with surgery, 
especially emergency surgery. [58, 64] 
Platelet inhibitors are mainly used in treating patients with cardio- or 
cerebrovascular disease. The modern-day inhibitors are very potent, leading 
to larger perioperative bleeding compared to patients without platelet 
inhibition. [196] Because of the risk of stent thrombosis in patients having 
undergone percutaneous coronary intervention (PCI) with stent, 
discontinuation of antiplatelet therapy must be discussed with a cardiologist. 
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[37] Acetylsalicylic acid (ASA) is also potent, irreversibly inhibiting the 
platelets, and there is an effect on perioperative bleeding. [55] Whether this 
effect is clinically relevant is still debated.  
Non-steroidal anti-inflammatory drugs (NSAID) are common over-the-
counter drugs to treat conditions such as headaches, fever and pain. Like 
acetylsalicylic acid they inhibit platelet aggregation and hence reduce blood 
clotting. Depending on the specific pharmacodynamics properties of the 
NSAID, their influence on coagulation differs. New NSAID that selectively 
inhibits cyclo-oxygenase-2 have no impact on platelet aggregation. [158, 
191] 
Selective serotonin reuptake inhibitors (SSRI) increase the risk of bleeding 
and transfusion in surgery. [17, 164, 201] Activated platelets expel serotonin 
into plasma and it is used to help platelet aggregation. Platelets have a similar 
serotonin transporter to that present on presynaptic neuronal endings, so it is 
likely that the platelet transporter is inhibited by SSRI in a similar way as in 
the central nervous system. [150] 
In patients experiencing blood loss, the first measure to take is to replace 
blood with intravenous fluids, colloids or crystalloids. This, together with 
consumption of coagulation factors caused by bleeding, may result in 
dilutional coagulopathy. Artificial colloids are known to affect blood clotting 
more than crystalloids and the reason might be inhibition of fibrin formation 
since the addition of fibrinogen reverses the effect of colloids on clot 
formation. [60, 63, 130, 160]  
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Table 2. Antithrombotic drugs and their indications, a selection. [3] 
 
  
Name Function Indication 
Heparin Indirect inactivation of 
thrombin and FXa 
Heparin lock in indwelling venous catheters, 
anticoagulant during extracorporeal circulation 
Low Molecular  
Weight 
Heparin 
Inhibition of activated 
factor X 
Venous thromboembolism, thrombosis 
prophylaxis 
Warfarin Inhibition of vitamin 
K-dependent 
coagulation factors II, 
VII, IX, X 
Venous thromboembolism, thrombosis 
prophylaxis, anticoagulation in patients with 
valve replacement or atrial fibrillation 
Dabigatran Thrombin inhibitor Venous thromboembolism, thrombosis 
prophylaxis, anticoagulation in patients with 
atrial fibrillation 
Rivaroxaban Inhibition of activated 
factor X 
Venous thromboembolism, thrombosis 
prophylaxis, anticoagulation in patients with 
atrial fibrillation, prophylaxis after acute 
coronary syndrome 
Apixaban Inhibition of activated 
factor X 
Venous thromboembolism, thrombosis 
prophylaxis, anticoagulation in patients with 
valve replacement or atrial fibrillation 
Acetylsalicylic 
acid 
Inhibition of platelet 
aggregation through 
cyclo-oxygenase 
Acute myocardial infarction, prophylaxis against 
cardio-vascular complication after acute coronary 
syndrome, prophylaxis against cerebrovascular 
disease 
Dipyridamol Inhibition of platelet 
aggregation  
Secondary prevention of cerebrovascular disease 
Clopidogrel Inhibition of platelet 
aggregation through 
inhibition of the P2Y12 
receptor 
Prevention of atherothrombotic events in patients 
with myocardial infarction or acute coronary 
syndrome, treated with or without PCI, 
anticoagulation in patients with atrial fibrillation 
Prasugrel Inhibition of platelet 
aggregation through 
inhibition of the ADP 
receptor 
Prevention of atherothrombotic events in patients 
who have had PCI with stent 
Ticagrelor Inhibition of platelet 
aggregation through 
inhibition of the ADP 
receptor 
Prevention of atherothrombotic events in patients 
with myocardial infarction or acute coronary 
syndrome, treated with or without PCI or 
coronary bypass surgery 
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1.2.3 Fibrinogen 
The main function of fibrinogen in the coagulation cascade is as the precursor 
to fibrin, which in turn forms the fibrin clot.  
 
Figure 3. Fibrinogen hexamer. With permission from the Protein Data Bank in 
Europe. [83] 
Fibrinogen is composed of three homologous polypeptide chains – A!, B" 
and # – forming two identical sets joined together to make a dimer structure. 
[163] Fibrinogen is primarily expressed and formed in liver cells and it is 
secreted in its hexamer form. [190] Cleavage of the A!-chain by thrombin 
initiates the formation of the fibrin clot at the site of bleeding. [162] The 
structure of the fibrin clot formed is affected by the amount of thrombin 
available – low levels of thrombin create a tighter fibrin clot. [26] The 
fibrinogen or fibrin #-chain contains the site for FXIII cross-linking. [209] 
The normal fibrinogen plasma concentration is 2.0-4.5 g/L and levels >1.0 
g/L are considered enough to maintain hemostasis. [218] In the bleeding 
patient, recent guidelines suggest that fibrinogen levels should be kept above 
1.5-2.0 g/L. [131]  
Congenital afibrinogenemia is a rare disease (prevalence 1 in 1,000,000) that 
usually manifests with umbilical cord bleeding in the neonatal period. [53] In 
contrast to hemophilia patients, bleeding in different joints is not common in 
patients with afibrinogenemia. Instead, bleeding occurs in the skin, 
genitourinary and gastrointestinal tract, and intracranial hemorrhage is a 
major cause of death in these patients. [178] Fibrinogen is vital for pregnancy 
and first trimester abortion is common in women with afibrinogenemia. [53] 
Patients with hypofibrinogenemia or dysfibrinogenemia are usually 
asymptomatic. [149, 152] Dysfibrinogenemia patients may experience both 
bleeding and thromboembolic complications. [152] Defective thrombin 
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binding, leading to increased levels of thrombin, and an abnormal fibrin clot 
resistant to fibrinolysis are the probable mechanisms behind this paradoxical 
clinical presentation. [53] 
In the bleeding patient, fibrinogen is consumed and it is the first coagulation 
factor to reach critically low levels in massive blood loss. [98] Compared to 
some of the other coagulation factors, fibrinogen is used up once it has been 
transformed into fibrin and incorporated in the fibrin clot. Sufficient plasma 
concentration is therefore necessary to maintain hemostasis in the bleeding 
patient. [131, 216] 
Fibrinogen is an acute phase reactant and fibrinogen plasma concentration 
increases for instance due to trauma, surgery, inflammation or infection. 
[173, 188, 207, 227] In a study comparing postoperative fibrinogen plasma 
concentration between patients who did versus did not receive intraoperative 
fibrinogen supplementation, there was no statistical difference between the 
two groups. [213]  
Fibrinogen derived from human plasma is commercially available with the 
indication congenital hypo- or afibrinogenemia. Today, fibrinogen 
concentrate is mainly used in patients with acquired hypofibrinogenemia 
because of massive blood loss and consumption due to trauma or surgery as 
described above, and its use is increasing. [212] The development of 
recombinant fibrinogen is desired and is advancing. Using a human cell line 
transfected with optimized cDNA encoding the fibrinogen Aα, Bβ and γ 
chains, fibrinogen can be produced in a controlled setting. [186] In an ex vivo 
setting, recombinant fibrinogen has been shown to have similar pro-coagulant 
characteristics as plasma-derived fibrinogen on blood samples from cardiac 
surgery patients.  However, further studies are needed before recombinant 
fibrinogen can be used in clinical practice. 
 
1.2.4 Factor XIII 
Coagulation factor XIII is a plasma pro-transglutaminase with multiple 
functions not only in coagulation but also in a wide range of physiological 
and pathological processes. Factor XIII exists in an extracellular form, 
circulating in plasma, and an intracellular form. The main function of FXIII 
is to cross-link with fibrin to stabilize the fibrin clot and protect it from 
fibrinolysis. [209] 
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Figure 4. FXIII tetramer. With permission from the Protein Data Bank in Europe. 
[83] 
 
Plasma FXIII (pFXIII) consists of two potentially active, catalytic A subunits 
(FXIII-A) and two inhibitory B subunits (FXIII-B), together forming a 
tetramer FXII-A2B2. Factor XIII-A is a transglutaminase consisting of 732 
amino acids and is mainly synthesized by cells of bone marrow origin. 
However, when bone marrow function is impaired cells of unknown origin 
take over the production of FXIII-A. Factor XIII-B is a glycoprotein 
consisting of 641 amino acids and is synthesized in the liver. [248] The two 
subunits form their tetrameric complex in the circulating blood. In plasma, 
FXIII-A circulates only in its fully complexed form, while approximately 
50% of FXIII-B circulates in free, non-complexed form. [252] Factor XIII is 
effectively activated in plasma only on the surface of newly formed fibrin. 
[206]  
Cellular FXIII (cFXIII) is a dimer consisting of only FXIII-A, FXIII-A2; it 
can be found mainly in platelets and monocytes/macrophages but also in 
chondrocytes, osteoblasts and osteocytes. [6, 171] As opposed to pFXIII, 
cFXIII is activated by an increase in cellular Ca2+, a non-proteolytic 
mechanism. [168]  
Congenital FXIII deficiency is a rare bleeding disorder (estimated prevalence 
1:1,000,000 to1:5,000,000). [72] Mutations occur in the FXIII-A genome, 
more than 100 are identified so far, causing either absence of FXIII or 
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dysfunction in the synthesized protein. [197] Patients with congenital FXIII 
deficiency present with symptoms like severe bleeding, spontaneous 
intracranial hemorrhages, poor wound healing and spontaneous abortions. 
[101] 
 
Figure 1. Factor XIII (FXIII) crosslinks with fibrin in the fibrin mesh. 
 
Human plasma-derived FXIII is available and it is used in patients with 
congenital FXIII deficiency. In study settings, FXIII concentrate has been 
used in patients with acquired FXIII deficiency due to trauma or 
perioperative bleeding, with differing results. [77, 115, 128] Recently, 
recombinant FXIII has been tested in patients with congenital FXIII 
Fibrinogen
Thrombin activation
Fibrin mesh
Crosslinked fibrin mesh
FXIII
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deficiency, with promising results. [106, 123] The recombinant FXIII is 
manufactured in yeast cells and contains no mammalian or human products, 
thus minimizing the risk of transferring infectious, or other diseases. [146] 
1.2.5 Coagulation assays 
Various laboratory assays are used to investigate a patient’s coagulation 
status. The most common are PT and activated partial thromboplastin time 
(aPTT). These two tests are often routinely taken to assess preoperative 
coagulation status in patients scheduled for elective surgery. [126, 244] Other 
ways of measuring a patient’s coagulation capacity are by measuring 
individual coagulation factors known to influence perioperative hemostasis, 
such as fibrinogen, and also by using point-of-care (POC) analyses.  
Blood coagulation is a dynamic process and conditions can change quickly. 
The coagulation assays mentioned above are time consuming and are passé 
by the time the results arrive in the emergency or operating room. Both PT 
and aPTT only measure part of the coagulation cascade and the measurement 
ends at clot formation. Point-of-care analyses, such as viscoelastic tests and 
platelet aggregation assays, can be used to obtain faster information about a 
patient’s coagulation status, and also provide information on clot quality and 
fibrinolysis. At the same time, POC analyses require knowledge and 
experience in how to interpret the results. [69, 245] 
 
Prothrombin time 
Prothrombin time measures the extrinsic pathway. The assay is affected by 
the levels of the vitamin K-dependent coagulation factors II (prothrombin), 
V, VII and X, as well as very low levels of fibrinogen. [124] The test was 
first described in 1935 by Quick, therefore initially called Quick’s time, but 
the name was later changed to PT. [184, 185] Different reagents are used 
when measuring PT, giving different results especially in patients on oral 
anticoagulation treatment. Prothrombin time is therefore standardized as an 
International Normalized Ratio (INR). In Scandinavia, laboratories use the 
method developed by Owren, which only measures levels of factors II, VII 
and X. [124] Test results for the two tests in the normal range are similar. 
[100] 
A patient with a PT of <1.5 is considered to have a low risk of bleeding 
during and after surgery. [229] A recent study suggests that the best cut-off 
point for avoiding major bleeding during surgery is 1.1, which is notably 
lower than previous recommendations. [223] 
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Activated partial thromboplastin time 
Activated partial thromboplastin time is a test that roughly studies the 
intrinsic pathway of the coagulation cascade. In 1913, a test designed to 
confirm the diagnosis of severe hemophilia, called whole blood clotting time 
(WBCT) was developed. [139] The test was further refined in steps, until it 
finally became the test used today. [135, 183] Unlike WBCT, aPTT uses 
platelet-free plasma from blood-samples taken in citrated tubes. Samples are 
recalcified, and partial thromboplastin is added. The, often automated, photo-
optical apparatus then measures the time from when the test is initiated until a 
clot is formed. In order to speed up the time before the clot forms, an 
activator is added, hence the name activated PTT. Activated partial 
thromboplastin time is measured in seconds (s) and the reference interval for 
adults is 30-42 s.  
Functional deficits in factors VIII, IX, XI, XII, prekallikrein and high 
molecular weight kininogen, as well as severe deficits in factors V, X, II and 
fibrinogen can affect aPTT measurements. [124] 
In the latest guidelines, neither PT nor aPTT are recommended for routine 
preoperative testing of a patient’s coagulation status. [131] 
 
Fibrinogen 
Fibrinogen plasma concentration can be measured in different ways. The 
most common is the method described by Clauss in 1957. [49] This method 
actually measures the clotting time in diluted plasma and compares that time 
with reference plasma with known fibrinogen concentration. The test sample 
is saturated with thrombin so that the amount of thrombin in the original 
sample does not influence the clotting time. The method of Clauss is 
considered the most frequently used assay. 
The PT-derived fibrinogen assay measures the patient’s PT in platelet-poor 
plasma and compares it to the PT in plasma dilutions with known fibrinogen 
concentration.  
To measure protein concentration, various immunological assays, like ELISA 
or the immune-nephelometric method, may be used. In congenital 
dysfibrinogenemia there is usually a discrepancy between fibrinogen activity 
and antigen level. The fibrin clot may also be extracted, cleaned, dried and 
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then weighed. This is a time consuming test not often used in the clinical 
setting. 
The different assays are not comparable in terms of measured fibrinogen 
levels. [148] Fibrinogen assays are also influenced by pharmaceuticals, 
hemodilution and by the level of fibrinogen in the blood sample. [62, 142, 
148]  
In the acute situation, fibrinogen levels may be estimated using viscoelastic 
methods such as thromboelastography or thromboelastometry. There is a 
correlation between fibrinogen plasma concentration, as measured by Clauss, 
and thromboelastometry/thromboelastography results, but the viscoelastic 
results are not yet fully standardized. [159, 214, 231] 
 
Factor XIII 
The main reasons for analyzing FXIII are to measure FXIII activity in 
patients with suspected FXIII deficiency and to monitor substitution therapy 
in patients with congenital FXIII deficiency. [119] There are many different 
assays, both quantitative and qualitative and, to diagnose a deficiency the 
assays should be used in combination in order to reach the correct diagnosis 
and classification. [127] 
Quantitative assays activate FXIII with thrombin and Ca2+. In order to 
eliminate interfering fibrin formation, various measures such as high plasma 
dilution and fibrin polymerization inhibitory peptide, are used. Amine 
incorporation assays measure the binding of amine to FXIIIa. This method is 
highly sensitive and can detect a FXIII activity as low as 1% but the method 
is time-consuming and, because of the many steps involved the method 
cannot be automated and standardized. [119] 
The recommended screening test for FXIII activity is a quantitative assay 
based on ammonia release from FXIIIa. It was first described in 1969. [243] 
Modern assays measure a substrate protein that captures the released 
ammonia, and the consumption of the protein can be measured with 
photometric methods. [67, 117] The method is quick, automated and 
reproducible. Its drawbacks are the low sensitivity, and that it needs a parallel 
blank sample that can correct for the ammonia produced in the plasma from 
sources other than FXIIIa. [10] 
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The original test for the clot stabilizing protein was to create a fibrin clot and 
then to try to dissolve it in a urea or acid solution. [132] Clot solubility tests 
are still in use today, but because the test is not standardized – different clot 
activators, clot formation time, solvent, etc. are used – the test is not 
recommended for testing for FXIII deficiency testing. [127] 
In patients with a suspected congenital or acquired FXIII deficiency a low 
FXIII activity on a quantitative assay requires further investigation into the 
type of FXIII deficiency present. [127]  
In the bleeding patient, FXIII deficiency can be assumed to result from 
consumption and a fast evaluation of FXIII may be critical. Unlike 
measurement of fibrinogen, where there is a correlation between regular 
fibrinogen plasma concentration assays and viscoelastic tests, no such 
correlation is seen between viscoelastic tests and regular measurement of 
FXIII activity. [81] 
 
Viscoelastic tests 
Thromboelastography was designed by H Hartet and described in an article in 
1948. [89] The idea is that a blood sample is placed in a cup into which a pin 
is inserted. The cup oscillates and as the blood coagulates the pin starts to 
move along with the cup, figure 6. This movement increases as the viscosity 
of the blood sample increases, and this is recorded and analyzed. (Figure 7) 
Today, two different devices using the same principle of blood viscosity as a 
means to measure coagulation are in use – the Thromboelastograph® (TEG®) 
which is based on Hartet’s original design, and Thromboelastometry® 
(ROTEM®), which is a further development using the same principle as 
thromboelastography. [147]  
Sonoclot®, which measures the changes in mechanical impedance using 
ultrasound, is another bedside device first described by von Kaulla et al. in 
1975. [238] The set-up is similar to thromboelastography and 
thromboelastometry, with the difference that the measuring pin moves up and 
down in the blood sample. 
This section will focus on thromboelastometry, since it is the device used in 
Paper IV. However, thromboelastometry, thromboelastography and 
Sonoclot® produce largely comparable results. 
Malin S Carling 
21 
Blood samples are taken in a citrated tube. Ideally, the sample should rest for 
30 minutes before analysis, but the blood sample can be analyzed 
immediately if time is short. [236] The sample volume in the measuring cup 
is 340 µL and to that volume, reagents are added. (Table 4) The reagents are 
chosen depending on what part of the coagulation system is to be assessed. 
The thromboelastometry device is designed in such a way that the pipetting 
steps are automated. The cup is placed in a holder and raised so that the 
measuring pin is inserted into the cup. The analysis starts when the reagent is 
added to the cup. For a description of test results, see Table 3. 
 
Figure 2. Principle of thromboelastometry. Reproduced with permission from 
ROTEM®. 
Figure 3. Thromboelastogram. Reproduce with the permission of ROTEM®. 
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Because of the short time from blood sample to test result, 
thromboelastometry has become a widely used tool to monitor coagulation in 
the bleeding patient. In the latest guidelines from the European Society of 
Anaesthesiology (ESA) on management of severe perioperative bleeding the 
POC coagulation monitoring with viscoelastic tests is recommended. [131] 
Thromboelastometry and thromboelastography are known to be user 
dependent, results often vary, and test accuracy has not been widely studied. 
[47, 104] Reference ranges for the different assays have been developed, but 
results should be analyzed and acted upon based on the combined results 
from the assays. [134]  
Table 3. Test results 
Result Description Reference value 
Clotting time – CT Time from addition of start 
reagent until clotting begins 
INTEM: 137-246 s 
EXTEM: 42-74 s 
FIBTEM: 43-69 s 
Clot formation time – CFT Time from CT to when a 
clot is formed 
INTEM: 40-100 s 
EXTEM: 46-148 s 
Amplitude 10 minutes 
after CT – A10 
 INTEM: 44-68 s 
EXTEM: 43-65 s 
FIBTEM: 9-24 s 
Maximum clot firmness – 
MCF 
Maximum vertical 
amplitude of the graph 
INTEM: 52-72 mm 
EXTEM: 49-71 mm 
FIBTEM: 9-25 s 
Maximum lysis – ML Amount of lysis INTEM: 0-12 % 
EXTEM: 0-18 % 
s = seconds, mm = millimeter  
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Table 4. List of assays used in thromboelastometry analysis, its reagents and 
the interpretation of test results. 
Test Reagent Interpretation 
INTEM Ca2+, phospholipids, ellagic 
acid 
Coagulation through the intrinsic pathway 
EXTEM Tissue factor Coagulation through the extrinsic pathway 
HEPTEM Ellagic acid, heparinase The effect of heparin in heparinazed patients; 
compare HEPTEM with INTEM 
FIBTEM Cytochalasin D, tissue factor Coagulation without platelet activation 
APTEM Aprotinin, tissue factor Faster detection of fibrinolysis 
 
 
Platelet aggregation 
Platelet function is essential for blood coagulation but is difficult to evaluate. 
The standard platelet count only tells us the amount of circulating platelets 
but does not give any information on the quality and function of the platelets. 
As mentioned above, many different factors affect platelet function and, at 
least in patients prescribed platelet inhibitors, it is important to assess 
thrombocyte function before surgery.  
Various POC devices are available to assess platelet drug inhibition. 
Impedance aggregometry and light transmission aggregometry are two of the 
methods to measure platelet function in the clinical setting. Whole blood is 
used in order to avoid the potential activation of the platelets that may occur 
when the sample is centrifuged to form platelet-rich plasma. In impedance 
aggregometry a small electric current is transmitted through the blood sample 
between two platinum electrodes and, as the platelets aggregate on the 
electrodes, the electric resistance increases. Cardinal and Flower first 
described this method in 1979. [41] Light transmission aggregometry 
measures changes in light as platelets aggregate. Today, there are several 
POC devices available that are similar in design and test results, such as 
Multiplate® (Roche Diagnostics, Basel, Switzerland), VerifyNow® 
(Accumetrics, San Diego, CA, USA) or Chrono-Log® (Chrono-log, 
Havertown, PA, USA).  
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1.3 Patient blood management 
In 1628, the British physician William Harvey published his book on blood 
circulation. He described how blood was pumped through the body by the 
heart and flowed through the vessels. This knowledge formed the foundation 
for further research on the circulatory system, bleeding and transfusion. 
There is a debate on who performed the first human-to-human blood 
transfusion. [136] 
Doctor Richard Lower, UK, experimented on dog-to-dog transfusion in 1665, 
as described in several recordings in the Journal Book of the Royal Society. 
In 1667 he made a successful dog-to-man blood transfusion. Lamb blood was 
also used for transfusion but, because of several complications with this 
practice, the Pope issued a ban on the procedure in 1679. [136] 
The first documented human-to-human blood transfusion was performed on 
22 December 1818, and was published in 1819 by a British physician and 
obstetrician named James Blundell. As an obstetrician he saw the 
consequences of post-partum hemorrhage and saw blood transfusion as a way 
to treat this condition. [28] From that point on the practice of blood 
transfusion, although rare at first, became in use.  
Two discoveries made blood transfusion feasible and integrated in everyday 
clinical practice. The first was the discovery of the AB0 blood groups in 1901 
by Landsteiner. [133] The second was the introduction of sodium citrate to 
prevent the blood from clotting thereby enabling storage and blood-banking. 
[141] Two World Wars led to further development in transfusion practices 
and how to organize blood-banking and donors so as to ensure a constant 
supply of blood products. [31] 
At the start of transfusion history, whole blood was given. Today fresh whole 
blood transfusion has seen a revival in war medicine. The harsh conditions in 
medical facilities close to the battlefield do not provide the infrastructure 
needed for the modern blood-bank. At the same time, massive hemorrhage is 
one of the leading causes of death in warfare, and prompt transfusion can be 
life-saving. Fresh whole blood transfusion has therefor been in practice in 
several war situations with good results. [20, 217] 
Today, blood transfusions are a part of the clinical setting. In Sweden, 
approximately 100,000 people receive blood transfusion every year and, in 
2014, 462,629 blood units were donated. [1] However, the use of blood 
transfusions is declining, both because of increasing knowledge about 
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potential risks associated with transfusion but also because of better 
understanding about when and how to transfuse.  
 
1.3.1 Transfusion and fluid substitution 
In modern transfusion medicine, whole blood is divided into three 
components; erythrocytes, plasma and platelets, and transfusions are based on 
what the patient needs. Donated whole blood is centrifuged and the blood 
components are layered and thereafter stored into different storage bags.  
 
Red blood cells 
Red blood cells (RBC) is the most common blood component to be 
transfused. After separation from the other blood components, RBC are 
stored in an additive solution, in +2° - +6° C for up to 42 days. [1] Over time, 
the quality of the RBC decreases and changes in RBC takes place. This 
phenomenon is referred to as storage lesions and there are discussions on 
how they affect patients. [14, 56] 
 
Plasma 
Plasma transfusion has many potential advantages in the bleeding patient. It 
is a source of coagulation factors, a volume expander and a means to reverse 
the anticoagulant effect of drugs. Plasma is obtained either from whole blood 
donors, through separation, or from apheresis with plasma extracted from one 
donor. [21] Most of the plasma is frozen to -18°C within 6 to 8 hours after 
donation and is labeled fresh frozen plasma (FFP). When needed, FFP is 
thawed. Plasma can also be stored as liquid, non-frozen plasma in +2° - +6°C 
for up to 14 days. [170] However, studies on FFP show that it has little effect 
on bleeding and transfusion in patients undergoing surgery. [129] 
 
Platelets 
Platelets are responsible for the primary hemostasis and are first to arrive at 
the site of injury to the vessel wall. They are easily activated however and 
donated platelets, platelet concentrate, are stored at room temperature and in 
constant agitation. [167] Because of the risk of bacterial growth platelets 
cannot be stored for more than 5 to 7 days. [234] There are two methods to 
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prepare platelet concentrate; either pooled buffy coat platelets extracted from 
4 to 6 whole blood donors or apheresis platelets extracted from one donor. 
The advantage with apheresis platelets is that the recipients are exposed to 
less antigen stimulation. [234] 
 
Fluids 
The body is adaptable and can function with a certain amount of anemia as 
long as there is a sufficient blood pressure to ensure tissue perfusion. 
Consequently, the recommendation is to start replacing blood loss with 
crystalloid or colloid fluids. [131, 216] It is important to be aware that 
colloids can affect blood coagulation. [63] 
 
1.3.2 Hemostatic drugs 
There are many different drugs that can be given before, during and after 
surgery to boost blood coagulation. Depending on the type of surgery and the 
patient’s coagulation status the drugs can reduce perioperative bleeding and 
transfusion requirements. 
Table 5. List of hemostatic agents, information derived from www.fass.se [3] 
Hemostatic drug Sales name Content Indication 
Prothrombin 
complex 
concentrate (PCC) 
Ocplex® , 
Confidex®  
Human FII, FIX, 
FVII, FX, Protein 
C, Protein S 
Reversal of 
anticoagulation with 
vitamin K inhibitors 
Fibrinogen  Riastap® Human fibrinogen Congenital fibrinogen 
dysfunction or 
hypofibrinogenemia 
FXIII Cluvot® Human FXIII Congenital FXIII 
deficiency 
Recombinant 
FVIIa  
Novoseven® Eptacog alfa Congenital or acquired 
hemophilia 
Desmopressin Octostim® Desmopressin Congenital or acquired 
platelet dysfunction 
Tranexamic acid Pilexam® , 
Cyklokapron®  
Tranexamic acid Prevention and treatment 
of hyperfibrinolysis 
Local hemostatics For instance 
Tachosil®, Tiseel®, 
Evisel®  
Fibrinogen, 
thrombin, aprotinin, 
FXIII 
Local hemostasis 
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Coagulation factors 
Fresh frozen plasma contains a variety of coagulation factors, but their 
concentration in plasma might not be sufficient to restore coagulation. 
Concentrated, specific coagulation factors are therefore available. Many of 
them are primarily produced to treat patients with coagulation disorders, but 
they are also used to treat acquired coagulation disorders/dysfunctions. 
Prothrombin complex concentrate (PCC) contains vitamin K-dependent 
coagulation factors and is indicated for patients on oral anticoagulation with 
vitamin K inhibitors. [177] When reversing the anticoagulant effect in trauma 
or surgery patients, PCC should be administered in combination with vitamin 
K. The effect of PCC lasts for 6 to 8 hours and by then the reversal with 
vitamin K should have taken place.  
In patients with traumatic or surgical bleeding, the most critical coagulation 
factor is fibrinogen. Several studies show that fibrinogen substitution in 
patients with major bleeding and signs of fibrinogen deficit reduces bleeding 
and transfusion requirements. [61, 232, 249] 
Factor XIII is suggested to reduce bleeding and improve coagulation in 
surgery patients, even though results vary. [85, 115, 128, 203] In vitro studies 
show that FXIII increases clot firmness, but these results have not been 
confirmed in a clinical setting. [230, 231]  
Recombinant factor VIIa (Novoseven®) has been shown to reduce bleeding 
and transfusion requirements, but not mortality, in trauma patients. [93] In 
cardiac surgery patients, recombinant FVIIa reduces bleeding but increases 
the risk of thrombotic events. [74] Results in studies vary however, and 
current guidelines do not suggest routine use of recombinant factor VIIa other 
than as a last resort when other treatments have failed to control the bleeding. 
[131, 216] 
Desmopressin is a synthetic hormone that increases the release of von 
Willebrand factor on endothelial cells, thereby increasing platelet activation 
and aggregation. The intended use for desmopressin is in patients with mild 
hemophilia type A and von Willebrand disease. Studies show a small effect 
on transfusion requirements in surgery patients treated with desmopressin. 
[51]  
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Tranexamic acid 
Dr Blundell, who established blood transfusions, was an obstetrician trying to 
save women from post-partum hemorrhage. [28] Tranexamic acid (TXA) was 
also developed by obstetricians, but they were looking for a treatment for 
women with heavy menstrual bleeding. In the 1960s two research groups, in 
Japan and Sweden, simultaneously found the antifibrinolytic properties of 
trans-4-aminomethyl-cyclohexanecarboxylic acid, in short tranexamic acid. 
[155, 175] 
Another early use was to reduce bleeding during surgery in patients with 
bleeding disorders, but soon more and more applications for TXA were 
uncovered. [225] Today, TXA is used in different surgical settings such as 
gynecology and obstetrics, orthopaedics and cardiac surgery. It is also used as 
a local hemostatic in oral extraction and in nose bleeds. 
 
Figure 4. Working mechanism of tranexamic acid. T-PA=tissue plasmin activator. 
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Tranexamic acid binds to, and blocks, the plasminogen lysine binding site. 
Plasminogen is the precursor to plasmin, which facilitates the decomposition 
of the fibrin clot by fibrinolysis. When TXA hinders plasminogen from 
binding to fibrin at the lysine binding site, plasminogen cannot be activated 
to plasmin and fibrinolysis is slowed down. [225] 
Both intravenous and topical TXA are known to reduce perioperative 
bleeding and the number of transfusions in many different surgical settings 
where major blood loss is expected. [38, 73, 122, 225] Tranexamic acid is 
also a cheap drug, and by reducing the number of transfusions, the use of 
TXA in surgery is highly cost-effective. [111] The use of TXA has also been 
evaluated in trauma patients in a large randomized, placebo-controlled study, 
CRASH-2, including 20,211 patients. The results showed that mortality 
independent of cause and mortality from hemorrhage was significantly lower 
in patients receiving TXA compared to placebo. [176] 
 Questions have been raised on the safety of TXA with regards to 
thromboembolic events. The CRASH-2 study showed no difference in death 
from vascular occlusion. [176] A meta-analysis from 2012 on knee 
arthroplasty patients showed no increase in thromboembolic disease in 
patients receiving TXA. [250] In patients with ongoing thromboembolic 
disease and risk factors for thromboembolic events TXA should be given 
with caution and more studies are required in these patient groups. [131] 
 
Local hemostatic agents 
There are different types of agents for obtaining a local hemostatic effect. 
Some create a larger surface area on which coagulation can occur, while 
some also contain coagulation factors. [222] The role of local hemostatic 
agents in orthopaedic surgery is not established and studies differ as to the 
effect on bleeding and transfusion requirements. [8, 25, 42, 140]  
 
1.3.3 Indications for transfusion 
As stated above, RBCs transport oxygen to the tissues and assist somewhat in 
blood coagulation. Transfusion should therefore be given when the patients 
lacks sufficient oxygen transportation and is affected by anemia. 
Transfusions should also be considered as one of many measures to ensure 
sufficient oxygen transportation.  
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Not many years ago, RBC transfusions were seen as a way to replenish the 
patient and also to speed up recovery. Transfusions were given liberally, and 
apart from rare immunological reactions, transfusions were considered safe 
and without side effects. In the 1980s, this perception changed with the 
appearance of HIV and several transfusion-related transmissions of the virus. 
Even though screening tests for HIV had been developed, the debate about 
the safety and necessity for transfusion had begun. [204]  
It is important to differentiate between the bleeding patient and the non-
bleeding patient. In a bleeding patient, indications for transfusion are much 
more liberal, and in massive-bleeding patients, other methods than Hb levels 
are used to determine how the patient should be transfused. [131] 
 
The bleeding patient – intraoperative 
During surgery, bleeding is ongoing and the blood that is lost contains not 
only oxygen transporters but also important coagulation factors. The surgical 
trauma creates a consumption of coagulation factors and triggers fibrinolysis. 
[179] 
Under normal circumstances there is an overcapacity in oxygen transport, 
which means that the patient can handle a certain amount of bleeding as long 
as blood is substituted with fluids to maintain sufficient tissue perfusion. [23, 
131] Both colloids and crystalloids can be used, but it is important to 
consider the anticoagulant effect in synthetic colloids. 
With continuing bleeding, the blood loss reaches critical levels and 
transfusions are required to maintain tissue oxygenation. In a bleeding patient 
recommendations are to maintain the following parameters: [23, 131, 216] 
• Hb level > 70-90 g/L 
• Platelet count >100 x 109 
• Fibrinogen >2.0 g/L 
• Normothermia 
• Normal pH ~7.2 
• Calcium concentration, Ca 2+ > 1 mmol/L 
The rule of thumb is to give the patient what is lost through bleeding, which 
is a mixture of blood products that equals whole blood. In massive bleeding, 
transfusion packs are used with a predefined ratio of blood products, for 
instance 4 units of RBC, 4 units of FFP and one unit of platelets, or one unit 
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each of RBC, FFP and platelets. [131, 216] The optimal relationship between 
the different blood products is not fully established and more studies are 
needed. 
In a patient with an ongoing large bleeding, fibrinogen is consumed and 
reaches critical levels. Early supplementation with fibrinogen concentrate is 
therefore needed, so to avoid compromising formation of the fibrin clot. The 
recommendation is to give 2-4 g of fibrinogen concentrate to a patient that 
requires large transfusion. [131, 216] Often fibrinogen is part of a transfusion 
pack.  
It is not only critical to transfuse the right blood products; timing is also 
important. In order to maximize the effect of a transfusion pack, in 
combination with hemostatic drugs such as fibrinogen, patients need to be 
given the transfusions all together and as fast as the patient can tolerate. Red 
blood cells are needed for oxygen transport but also for helping platelets to 
migrate towards the vessel wall. Fibrinogen concentrate needs the 
coagulation factors in FFP to become activated to fibrin. Platelets are 
required to initiate coagulation and as a scaffold for propagation of clot 
formation. [23] 
Trauma induced coagulopathy (TIC), pathophysiology and treatment have 
attracted increasing interest. [13] In trauma patients, the nature of the injury 
mechanism affects coagulation. Body temperature is reduced. Acidosis 
occurs due to tissue damage and compromised tissue perfusion. Fracture and 
large wounds creates major activation of the coagulation cascade with 
consumption and a subsequent reduction in coagulation factors. Massive 
bleeding also reduces coagulation factors and compromise tissue oxygenation 
through hypotension and anemia. [40] 
 
Non-bleeding patients – postoperative 
A patient in a postoperative setting has a different need for coagulation 
management than in the intraoperative setting. The first large-scale attempt to 
establish transfusion triggers in critical care was the Transfusion Requirement 
in Critical Care trial, published in 1999. [96] In the study, 838 patients were 
either assigned to a restrictive transfusion strategy or to a liberal transfusion 
strategy. The restrictive transfusion group had an Hb threshold for 
transfusion of 70 g/L, while the liberal transfusion group had a threshold of 
100 g/L. The study showed no difference in mortality and morbidity between 
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these groups and the number of RBC units transfused were 54% lower in the 
restrictive transfusion group.  
This breakthrough study began a debate on when to transfuse. Several 
randomized studies have been carried out, reaching similar conclusion. A 
study on hip fracture patients saw no difference in death or ability to walk 
across a room 60 days after surgery between a liberal or restrictive 
transfusion protocol. [45] Similarly, a post-hoc analysis on elective hip or 
knee arthroplasty patients saw no difference in morbidity and mortality as 
well as Quality of Life and fatigue scores depending on transfusion regiment. 
[211] A Cochrane review from 2012 suggests that in non-bleeding patients 
without acute coronary heart disease, Hb levels of 70-80 g/L do not require 
RBC transfusion. [44] However, these suggestions were recently challenged 
by a randomized study in cardiac surgery patients where a more liberal 
transfusion regimen, Hb <90 g/L compared to Hb <75 g/L, was associated 
with lower mortality. [165]  
 
1.3.4 Risks associated with transfusions 
Transfusion of blood products may be lifesaving but may also be associated 
with increased morbidity and mortality in patients undergoing surgery. [39, 
70] It is however, difficult to distinguish between the risk of the underlying 
cause, for example excessive bleeding, and the risk of the blood transfusion 
per se. Known risks associated with transfusion are transmission of infectious 
microorganisms, immunological reactions and transfusion-related acute lung 
injury (TRALI). Today, measures are taken to minimize these hazards but 
patients still experience adverse effects from transfusions. 
The transmission of infections through transfusions has been known since the 
1940s and many measures, including screening and control of blood donors, 
have been taken to minimize these risks. [166] In modern transfusion 
practice, these measures have reduced the risk to extremely low levels.  
As part of the procedures relating to transfusions, immunological testing of 
the recipient and the blood given is performed. Since the discovery of the 
AB0 blood groups, several other blood groups, like Rhesus antigen, have 
been revealed. In an acute situation, where there is no time for sufficient 
blood group testing, group 0 RBC and AB plasma should be used. [179] 
Transfusion-related acute lung injury is nowadays considered a major cause 
of adverse events following transfusion. The first cases were described in 
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1983, and the connection with HLA antibodies was described, but it was not 
until 2003 and 2004 that the condition was defined. [151, 181] If acute lung 
injury (ALI) occurs within six hours of a plasma-containing blood component 
transfusion in a patient without previous ALI, it is considered to be TRALI. 
The definition for ALI is new onset hypoxemia (blood oxygen saturation 
<90% on room air), bilateral pulmonary infiltrates on chest x-rays, and 
without volume overload.  
TRALI is mostly associated with transfusion of FFP or pooled platelets, 
especially if the blood donor is female. [151]  
Studies indicate an increased risk of postoperative infection in patients who 
have received perioperative transfusion. [224] Other studies indicate an 
increased risk of recurrence of cancer in patients with perioperative 
transfusion at the first cancer surgery. The rationale behind these findings 
could be a transfusion-related immune modulation, but this theory is debated. 
[46, 235] 
 
1.3.5 Measures to prevent transfusion 
Erythropoietin 
Erythropoietin is a glycoprotein produced in the kidneys to stimulate RBC 
proliferation. Production of erythropoietin is oxygen-dependent and hypoxia 
leads to higher erythropoietin production. Recombinant erythropoietin is 
available and is used to treat anemia in patients with chronic renal failure, 
anemia due to certain malignancy, or in preoperative blood management. [68] 
Studies have been carried out where patients, preoperatively, are treated with 
erythropoietin and iron supplementation to stimulate RBC production. In 
orthopaedic surgery, erythropoietin reduces the need for RBC transfusion 
when compared to no treatment or iron supplementation alone, 
preoperatively. [59, 78, 242] Similar results have been seen in other types of 
surgery as well, and erythropoietin is considered to be of value for patients 
with mild preoperative anemia where nutritional or other reasons for anemia 
have been ruled out. [48, 131, 215]  
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Autologous blood transfusion 
Worries about the spread of hepatitis in the 60s and 70s saw an increase in 
autologous blood transfusion, i.e. the practice of a patient giving blood prior 
to elective surgery that can be used, if needed, during surgery. This practice 
was again increased when HIV was discovered. [256]  
Today, autologous transfusions should be considered as one of many ways to 
reduce allogeneic RBC transfusion. Many studies show that the 
indiscriminate use of preoperative autologous donation may not be cost-
effective and that many blood units are wasted. [24, 29, 92] Even though the 
number of allogeneic transfusions is decreasing, the overall number of 
transfusions is increasing, probably due to the risk of anemia after donation. 
[97, 121] However, for a selected group of patients with a high risk of 
transfusion, autologous transfusion is an option. [153] The recommendation 
is that these patients should be treated with erythropoietin after blood 
donation to avoid preoperative anemia. Studies show that the use of 
autologous transfusion is decreasing. [253, 254] In 2002 only 0.13% of all 
transfusions in Sweden were autologous. [76]  
 
Cell salvage 
Autotransfusion of shed blood during surgery was first described in 1860 
during an amputation. [35] Since then, the technique has been refined and is 
in clinical use in many settings, both intraoperatively and postoperatively. 
Several studies and meta-analysis have shown that the cell salvage technique 
reduces the use of allogeneic RBC transfusion. [33, 43, 103] There is a risk, 
however, that the salvaged RBC hemolyzes and that the suction blood 
impairs hemostasis. [84, 220] It is also considered that cell salvage should not 
be used in surgery for malignancy or infection, since there might be a risk of 
spreading malignant cells or infectious materials to the circulating blood. [57] 
These considerations are now under scrutiny and, at least for gastrointestinal 
surgery, one study has showed that intraoperative cell salvage is a safe 
practice. [34] 
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1.4 Study objectives 
Blood coagulation during surgery has not been widely studied in the 
orthopaedic surgery setting. This is in spite of the fact that orthopaedic 
surgery is one of the surgical fields with the highest transfusion rates. As 
stated above transfusion of blood products is not without complications and 
there are other measures can be taken to prevent transfusion. Both blood 
coagulation status as well as other patient- or procedure-related factors could 
influence perioperative bleeding and transfusion requirements.  
In Paper I, the goal was to identify preoperative indicators that could predict 
perioperative bleeding and transfusion requirements in a healthy group of 
patients undergoing a standardized orthopaedic surgical procedure, scoliosis 
surgery, known to be associated with relatively large bleeding volumes. 
Studies in other surgical fields, such as cardiac surgery, had shown that low 
fibrinogen was a risk factor for large bleeding and transfusion. Similar 
studies had not been carried out on orthopaedic surgery patients. 
Transfusion requirements vary, both between studies but also between 
different orthopaedic surgical procedures. The trend over recent years has 
been to minimize surgical trauma by, for example, using smaller incisions 
and using drainage less frequently. Paper II was initiated to study the 
perioperative bleeding and transfusion requirements, and the associated risk 
factors, in the everyday surgical setting in total hip and knee arthroplasty 
patients.  
The role of FXIII activity on perioperative bleeding and transfusion in 
surgery has not been established in orthopaedic surgery. In Paper III the 
objective was to investigate whether preoperative fibrinogen plasma 
concentration and FXIII activity could be useful tests for identifying patients 
at risk of perioperative bleeding, and transfusion requirements, in different 
groups of orthopaedic surgery patients.  
The effect of FXIII supplementation on clot formation has been studied but 
not in blood samples from patients undergoing surgery and not in clinically 
relevant doses. Paper IV was therefore designed to investigate whether ex 
vivo FXIII concentrate supplementation can improve clot formation and 
whether the combination with fibrinogen concentrate or platelet 
supplementation alters the effect of the added FXIII concentrate.  
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2 AIM 
The overall aim of the thesis was to investigate whether there is a relationship 
between coagulation factors and perioperative bleeding and transfusion in 
elective orthopaedic surgery patients.  
The specific aims were: 
• To study the relationship between preoperative fibrinogen 
plasma concentration and perioperative bleeding and 
transfusion requirements in idiopathic scoliosis surgery 
patients, degenerative spine surgery patients and arthroplasty 
patients. (Papers I and III) 
 
• To describe perioperative bleeding and transfusion in hip 
and knee arthroplasty patients. (Paper II) 
 
• To identify risk factors for excessive bleeding and 
transfusion in hip and knee arthroplasty patients. (Paper II) 
 
• To study the relationship between fibrinogen and 
coagulation factor XIII activity and perioperative bleeding 
and transfusion requirements in hip and knee arthroplasty 
and degenerative spine fusion surgery patients. (Paper III) 
 
• To study the ex vivo effect of FXIII supplementation, alone 
or in combination with fibrinogen or platelets, on clot 
formation in blood samples from cardiac surgery and 
idiopathic scoliosis surgery patients. (Paper IV) 
  
  
 
 
Patients and 
methods 
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3 PATIENTS AND METHODS 
 
3.1 Ethics 
All studies were approved by the Research Ethics Committee at the 
University of Gothenburg. 
 
3.2 Patients 
Paper I 
Eighty-two otherwise healthy patients with adolescent idiopathic scoliosis, 
undergoing posterior scoliosis surgery were included in the study. Patients 
were recruited and underwent surgery at Sahlgrenska University Hospital. 
 
Paper II and III 
The studies involved 245 patients undergoing either spine fusion surgery 
involving two or more spinal segments (n=52), elective total unilateral 
primary hip arthroplasty (THA) (n=114), or knee arthroplasty (TKA) (n=79). 
In Paper II only the hip and knee arthroplasty patients were investigated. 
Patients were recruited from a university hospital (Sahlgrenska University 
Hospital, Gothenburg, Sweden) and a municipal hospital (Kungälv Hospital, 
Kungälv, Sweden) between October 2009 and January 2011. Hip and knee 
patients underwent at both hospital, and spine patients solely at the university 
hospital.  
The exclusion criteria were known liver disease and/or coagulation disorder. 
Patients on acetylsalicylic acid (ASA) or non-steroidal anti-inflammatory 
drugs (NSAID) were urged to discontinue these medications at least three 
days before surgery, according to the local guidelines. Patients on warfarin 
treatment were bridged with low molecular weight heparin (LMWH). 
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Paper IV 
Nine patients undergoing cardiac surgery with cardiopulmonary bypass 
(CPB) and ten patients undergoing scoliosis surgery for adolescent idiopathic 
scoliosis were included in the study. Patients were recruited and underwent 
surgery at Sahlgrenska University Hospital. For cardiac surgery patients, 
clopidogrel or ticagrelor was discontinued at least five days before surgery. 
None of the scoliosis surgery patients were on any medication influencing 
coagulation or platelet function.  
Table 6. Patient characteristics 
 Paper I Paper II and III Paper IV 
Type of 
surgery 
Scoliosis 
surgery 
n = 82 
THA 
n = 114 
TKA 
n = 79 
Spine 
surgery 
n = 52 
Cardiac 
surgery 
n = 9 
Scoliosis 
surgery 
n = 10 
Gender 
(Female) 
70 (85%) 52 (46%) 47 (59%) 27 (52%) 0 8 (80%) 
Age 
(years) 
15 ±3 66 ±12 69 ±10 62 ±12 67 ±2 16 ±2 
BMI 
(kg/m2) 
20.8 ±4.4 27.2 ±4.1 30.0 ±4.4 26.8 ±4.4 27.5 ±0.9 18.7 ±1.1 
BMI = body mass index, THA = total hip arthroplasty surgery, TKA = Total knee arthroplasty 
surgery 
 
3.3 Methods 
 
3.3.1 Clinical management 
Type of surgery 
In Papers I and IV, all scoliosis surgery patients underwent posterior 
instrumented fusion. In Papers II and III, in the THA group, 55 patients 
(56%) received cemented prostheses, 25 (25%) received uncemented 
prostheses, 9 (9%) underwent a hybrid procedure (with an uncemented 
acetabular component and a cemented femoral component), and 10 patients 
(10%) underwent a reverse hybrid procedure (with a cemented acetabular 
component and an uncemented femoral component). All the patients in the 
TKA group received cemented knee prostheses, and all operations were 
carried out in bloodless field. The spine patients all underwent an 
instrumented lumbar or thoracolumbar fusion, and the number of segments 
fused ranged from 2 to 15, median 4. 
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In Paper IV, the cardiac surgery patients underwent coronary artery bypass 
surgery. 
 
Anesthesia 
In Papers I and IV, scoliosis surgery patients underwent surgery under total 
intravenous anesthesia. In Papers II and III, spinal anesthesia was used for 
160 of the patients (95 THA and 65 TKA), and general anesthesia was used 
for the remaining patients, including all the spine patients. 
In Paper IV, all cardiac surgery patients were operated with CPB. Before 
cannulation, heparin (Lövens, Ballerup, Denmark), 300 IU/kg, was given and 
supplemented as required to maintain an activated clotting time of more than 
480 seconds. CPB was performed with a hollow-fiber membrane oxygenator. 
The operations were performed with standard nonpulsatile CPB technique in 
normothermia and hemodilution (hematocrit 20-30%). A standard flow of 2.4 
L ×	 min ×	 m-2 was used. Cardioprotection was achieved with cold blood 
cardioplegia. No topical cooling was used. Weaning off CPB was performed 
at a temperature of at least 36°C. Protamine (1 mg protamine per 100 units of 
heparin) was given to reverse the effect of heparin. 
 
Tranexamic acid 
In Paper I, all patients received 1 g of tranexamic acid (TXA) intravenously 
at the initiation of surgery. In Papers II and III, all THA and TKA patients 
received TXA perioperatively according to local routine. Seventeen (33%) of 
spine patients received TXA either before surgery or when bleeding, 
according to the individual surgeons preference. In Paper IV, all cardiac 
surgery patients received 2 g of TXA before initiation of surgery and after 
wound closure. In scoliosis surgery five patients received TXA at the 
initiation of surgery. 
 
Thrombosis prophylaxis 
In Paper I, patients received thrombosis prophylaxis with either LMWH or 
colloid infusion. Fifty-six patients received LMWH for seven days or until 
mobilized, with the first dose the day before surgery. The remaining 28 
patients received Macrodex® 500 mL on the day of surgery and the following 
five days. 
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In Papers II and III, the new oral anticoagulant (NOAC) dabigatran was 
used as thrombosis prophylaxis in 104 THA patients and 75 TKA patients 
while the rest of the patients including all spine patients received LMWH. 
The first dose of dabigatran was administered in the evening after surgery 
while the first dose of LMWH was given the evening before surgery. 
In Paper IV, all scoliosis surgery patients received LMWH with the first 
dose administered the evening before surgery. Cardiac surgery patients 
received LMWH, the first dose administered the morning after surgery.  
 
Transfusion 
In Paper I, red blood cell (RBC) transfusion was given when the hemoglobin 
(Hb) level decreased to <80 g/L. In Papers II and III, no specific transfusion 
protocol or transfusion triggers were used. In Paper I a cell saver was used 
for all patients and intraoperative autotransfusion of processed RBC was 
performed if the cell saver volume exceeded 400 mL.  
 
3.3.2 Blood sampling and analysis 
Sampling 
In Paper I, blood samples were collected within 24 hours before surgery for 
analysis of Hb, platelet count, prothrombin time (PT), activated partial 
thromboplastin time (aPTT) and fibrinogen plasma concentration. 
In Papers II and III blood samples were taken from a peripheral vein within 
24 hours before surgery. Samples for PT, aPTT, fibrinogen and FXIII were 
collected in citrated tubes (0.129 M à 2.7 mL). The samples for fibrinogen 
and FXIII were centrifuged and the plasma was stored in -80°C for further 
analysis. Samples for Hb analysis and platelet count were collected in EDTA 
tubes (1.8 g/L). 
In Paper IV blood samples were collected from an arterial line except in two 
scoliosis surgery patients where blood was collected from a peripheral 
venous catheter dedicated for blood sampling. Preoperative blood samples for 
both cardiac and scoliosis surgery patients were collected after the induction 
of anesthesia but before surgery started. In cardiac surgery patients, 
postoperative blood samples were collected when the patient was off CPB 
and after heparin had been neutralized with protamine. In scoliosis surgery 
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patients, blood samples were collected immediately on completion of 
surgery. Samples for ROTEM®, fibrinogen and FXIII analysis were collected 
in citrated tubes (0.129 M à 2.7 mL). The samples for fibrinogen and FXIII 
analysis were centrifuged and the plasma was stored in -80°C for further 
analysis. Samples for Hb analysis and platelet count were collected in EDTA 
tubes (1.8 g/L). 
 
Analysis 
In Papers I-IV Hb, platelet count, PT and aPTT were analyzed using clinical 
standard methods.  
In Papers I, III and IV fibrinogen plasma concentration was measured by 
the modified method by Clauss (STA®-R; Diagnostica Stago, Asnieres, 
France), with a reference value of 2.0-4.5 g/L. [49] In Papers III and IV the 
FXIII activity was measured using a photometric method with a reference 
value of 0.7-1.4 kIU/L or 70-140% (Berichrom FXIII/Dade Behring, 
Marburg, Germany). [67] 
In Paper IV clot formation was analyzed with thromboelastometry 
(ROTEM®, Pentapharm GmbH, Munich, Germany). 
 
3.3.3 Definitions and calculation of bleeding 
In Papers I, III and IV, perioperative bleeding in scoliosis and spine surgery 
patients and cardiac surgery patients was defined as intraoperative bleeding 
calculated from wound suction plus the estimated amount of blood in the 
cloths used, and drainage volumes in combination with postoperative 
bleeding which were drainage volumes during the first 24 h. 
In Papers II and III, THA and TKA patients did not receive any 
postoperative drains and, for the TKA patients, bloodless field was also used, 
which meant that total bleeding could not be measured as described above. In 
these patients, perioperative bleeding was estimated instead based on the drop 
in Hb between the preoperative measurements and the measurements 24–48 h 
postoperatively, according to a formula developed by Brecher. [36] The 
formula used was as follows:  
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Estimated blood loss (EBL) = ((‘estimated blood volume (EBV)’ × 
‘hematocrit preoperatively’ - EBV × ‘hematocrit postoperatively’) + (‘RBC 
transfusion’ × 200 + ‘intraoperative cell salvage’ × 0.55)) / 0.35. 
For EBV, the formula is as follows: EBV = (0.0235 × (height in cm)0.42246 × 
(weight in kg)0.51456) × k, where k = 2.430 for women and 2.530 for men (12). 
In Paper I, extensive bleeding was defined as bleeding in the upper quartile 
(>1920 mL), and extensive transfusion was defined as >2 units of RBC. 
Patients with a bleeding of ≤1920 mL were defined as normal bleeders. 
In Paper II patients in the upper 75th percentile of EBL/kg in the THA and 
TKA group respectively, were defined as excessive bleeders while all other 
patients were considered to be non-excessive bleeders. 
In Paper III large bleeding was defined as >2,000 mL and large transfusion 
was defined as RBC >2 units and/or transfusion of ≥500 mL cell saver-
processed blood. [19, 200] 
 
3.3.4 Preparation of samples 
In Paper IV, preoperative clot formation was analyzed in whole blood 
without additives. Postoperatively, ten different samples were prepared for 
each study subject; one baseline and three with increasing doses of FXIII 
concentrate (Fibrogammin®, CSL Behring, Marburg, Germany) (+20, +40 
and +60%) alone or in combination with a fixed dose of fibrinogen 
concentrate (+1.0 g/L) (Riastap®, CSL Behring) or freshly made apheresis 
platelets (+92 ×	 109 ×	 L-1) from the institutional blood bank. Phosphate-
buffered saline (PBS), 140 mM NaCl, 10 mM Na3PO4, pH 7.4) was used in 
different volumes to keep the same hemodilution in the samples. All samples 
for clot formation analysis had a total volume of 987 µL thereof 760 µL 
citrated whole blood. 
 
3.3.5 Statistical analysis 
In Papers I-IV, statistical significance was defined as a p-value of <0.05. 
Data are presented as mean and standard deviation, median and range, or 
numbers and percentage where appropriate. Continuous variables were 
compared with Student t-test or Mann-Whitney U-test, depending on 
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distribution, and categorical variables were compared with Chi-square test. In 
the statistical analyses PT was considered a continuous variable.  
In Paper I, correlation between laboratory variables and bleeding were 
calculated with Pearson test.  
In Paper II, statistical models for identification of predictors of blood loss 
and transfusion were made with logistic regression analysis. For multiple 
regression analysis, stepwise logistic regression analysis was used.  
In Paper III, baseline and perioperative variables in the three surgery groups 
were compared using an ANOVA or Kruskal-Wallis test, depending on 
distribution. Changes within a group were compared with paired t-test or 
Wilcoxon rank-sum test, as appropriate. 
In Paper IV, factor analysis was used to identify the difference in ROTEM® 
results between the different blood samples prepared. Calculations were done 
on logarithmic data in order to produce a normal distribution. Factor XIII 
dose was used as a fixed factor while patient and treatment, FXIII alone or in 
combination with fibrinogen or platelets was used as random factors. 
For statistical calculations, SPSS software version 18.0 was used for Paper I 
and version 20.0 for Papers II-IV. (IBM Corp., Armonk, NY, USA) 
  
  
Results 
 
Malin S Carling 
47 
4 RESULTS 
 
4.1 Paper I 
Patient characteristics, hemostatic variables  and bleeding and transfusion 
data are presented in Table 7. Patients defined as bleeders (perioperative 
bleeding >1920 mL) had a longer operation time, were more likely to be on 
colloid prophylaxis and had a lower preoperative fibrinogen concentration 
compared to normal bleeders (perioperative bleeding ≤1920 mL), Table 8. 
Patients needing extensive transfusion, defined as >2 units of RBC 
transfusion, had a higher total bleeding volume, a lower preoperative 
fibrinogen concentration, were more likely to be on colloid prophylaxis, were 
more likely female, and had a lower body mass index (BMI). 
The positive and negative predicting values for extensive total bleeding for a 
preoperative fibrinogen concentration cut-off level of 2.8 g/L, were 47% and 
94%, respectively. The corresponding values for extensive transfusion were 
30% and 88%, respectively. 
Total bleeding volume correlated significantly with preoperative fibrinogen 
concentration (r= -0.31, p=0.005) but not with platelet count, activated partial 
thromboplastin time (aPTT) nor prothrombin time (PT) (p=0.61, 0.46 and 
0.57, respectively), Figure 9. 
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Table 7. Patient hemostatic variables, and bleeding and transfusion data for 
patients in Papers I-III.  
 Paper I Paper II and III 
Type of surgery Scoliosis 
surgery 
n = 82 
THA 
n = 114 
TKA 
n = 79 
Spine surgery 
n = 52 
Hb 
(g/L) 
137 ±12 136 ±12.7 133 ±12.3 124 ±14.0 
Platelet count 
(109/L) 
308 ±70 283 ±64.7 280 ±72.0 263 ±70.2 
PT 
(INR) 
1.1 ±0.1 1.0 ±0.1 1.0 ±0.1 1.1 ±0.093 
aPTT 
(s) 
35 ±3 34 ±3.8 33 ±3.3 36 ±4.7 
Fibrinogen 
(g/L) 
3.0 ±0.7 3.3 ±0.67 3.4 ±0.58 3.0 ±0.78 
Factor XIII 
(kIU/L) 
- 1.17 ±0.24 1.25 ±0.24 1.06 ±0.23 
Operation time 
(min) 
194 ±50 125 ±28.0 113 ±28.2 247 ±77.5 
Total bleeding 
(mL) 
1552 ±1019 984  
(0-4,751) 
758  
(0-1,927) 
1,715  
(400-7,420) 
Perioperative 
RBC transfusion 
30 (37%) 21 (18%) 9 (11%) 35 (67%) 
Extensive transfusion 
(> 2 RBC Units) 
13 (16%) 2 (2%) 1 (1%) 18 (35%) 
Large transfusion 
(> 2 RBC Units or  
> 500 ml cell salvage) 
- 4 (3%) 1 (1%) 25 (48%) 
THA = total hip arthroplasty surgery, TKA = total knee arthroplasty surgery, Hb = hemoglobin 
level, PT = prothrombin time, aPTT = activated partial thromboplastin time, RBC transfusion 
= red blood cell transfusion 
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Table 8. Pre- and perioperative variables in bleeders (>1920 mL) vs. normal 
bleeders (≤1920 mL) and patients with extensive transfusion (>2 units of 
RBC) vs. patients with no or limited transfusion.  
 Bleeders 
n = 20 
Normal 
bleeders 
n = 62 
Extensive 
RBC transfusion 
n = 13 
No or limited 
RBC transfusion 
n= 69 
Age  
(years) 
15 ±3 15 ±3 15 ±2 16 ±3 
Female 
(n) 
15 (75%) 55 (89%) 12 (92%)*** 58 (84%)*** 
BMI  
(kg/m2) 
20 ±3 21 ±5 18 ±1* 21 ±5* 
Operation 
time 
(s) 
221 ±56** 156 ±45** 205 ±54 192 ±49 
Colloid 
prophylaxis 
13 (65%)** 15 (24%)** 9 (69%)** 19 (28%)** 
Fibrinogen 
(g/L) 
2.6 ±0.6*** 3.1 ±0.6* 2.5 ±0.5** 3.1 ±0.6** 
PT  
(INR) 
1.1 ±0.1 1.1 ±0.1 1.1 ±0.1 1.1 ±0.1 
aPTT  
(s) 
36 ±3 36 ±3 36 ±4 36 ±3 
Platelet count 
(109/L) 
301 ±63 310 ±71 285 ±62 312 ±70 
Hb  
(g/L) 
138 ±9 136 ±13 136 ±8 137 ±12 
RBC 
transfusion 
3.0 ±2.4*** 0.4 ±0.9*** - - 
Total 
bleeding (ml) 
- - 2964 ±1382** 1286 ±669** 
* p < 0.05, **p < 0.01, ***p < 0.001 vs. excessive bleeding or extensive transfusion. BMI = 
body mass index, Hb = hemoglobin level, PT = prothrombin time, aPTT = activated partial 
thromboplastin time, RBC transfusion = red blood cell transfusion 
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Figure 5. Correlation between total bleeding volume and preoperative fibrinogen 
plasma concentration (A), prothrombin time (B), activated thromboplastin time 
(C), and platelet count (D). The equation for the logarithmic fit line in (A) is y = 
3319 - 3807*log10(x). 
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4.2 Paper II 
Patient characteristics are presented in Table 7, page 48. All patients survived 
the perioperative period and there were no major complications except in one 
total hip arthroplasty (THA) patient who was re-operated because of 
inappropriate stem placement, and one total knee arthroplasty (TKA) patient 
who was re-operated because of early, deep infection.  
Observed median intraoperative bleeding for THA patients was 450 mL 
(150-3,000 mL) and for TKA patients 0 mL (0-600 mL). Median estimated 
blood loss (EBL) was 984 and 758 mL for THA and TKA patients, 
respectively. There was a significant difference between observed 
perioperative bleeding and EBL for both THA and TKA patients, Figure 10. 
 
Figure 6. Observed and estimated median perioperative bleeding in patients 
undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA). 
 
Univariate regression analysis results are presented in Table 9 and Table 10 
for THA and TKA patients, respectively. 
For THA patients a multiple regression analysis, female gender (odds ratio 
(OR) 3.91, 95% CI 1.41-10.88 per kg, p=0.009), low BMI (OR 0.82, 95% CI 
0.71-0.94 per unit, p=0.005), and long operation time (OR 1.03, 95% CI 
1.01-1.05 per min, p=0.004) increased the risk for excessive bleeding. 
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Preoperative Hb was the only factor significantly predictive of allogeneic 
RBC transfusion (OR 0.87, 95% CI 0.82-0.93 per g/L, p<0.001). 
For TKA patients a multiple regression analysis, low BMI (OR 1.1, 95% CI 
0.64-0.93 per unit, p=0.006) and high preoperative Hb (OR 1.11, 95% CI 
1.04-1.17 per g/L, p=0.001) increased the risk of excessive bleeding. In 
multiple regression analysis, low BMI (OR 0.71 95% CI 0.51-0.98 per unit, 
p=0.034), low preoperative Hb (OR 0.71 95% CI 0.51-0.98 per g/L, 
p=0.015), and long operation time (OR 1.04 95% CI 1.00-1.07 per minute, 
p=0.036), increased the risk for RBC transfusion.  
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Table 9. Univariate risk factor analysis in THA patients for excessive 
bleeding and transfusion 
 Excessive bleeding 
(EBL/kg >17.1 ml/kg) 
Allogeneic RBC transfusion 
 
 
OR 95% CI P value OR 95% CI P value 
Age (years) 
 
1.00 0.99 - 1.07 0.11 1.05 1.01 - 1.10 0.022 
Sex(F) 
 
3.39 1.37 - 8.38 0.008 7.04 2.19 - 22.63 0.001 
BMI (kg/m2) 
 
0.83 0.73 - 0.95 0.006 0.90 0.79 - 1.03 0.13 
Weight (kg) 
 
0.92 0.89 - 0.96 <0.001 0.94 0.91 - 0.98 0.003 
NSAID (No) 
 
1.42 0.51 - 3.93 0.50 0.66 0.24 - 1.83 0.42 
ASA (No) 
 
1.17 0.35 - 3.89 0.80 0.75 0.22 - 2.57 0.65 
SSRI (No) 
 
0.45 0.12 - 1.73 0.24 0.29 0.08 - 1.15 0.079 
Hemoglobin 
(g/L) 
 
0.97 0.94 - 1.01 0.12 0.87 0.82 - 0.93 <0.001 
Platelet count 
(109/L) 
 
1.01 1.00 - 1.01 0.17 1.00 1.00 - 1.01 0.52 
PT (INR) 
 
0.76 0.001 - 70.9 0.90 0.03 0.00 - 7.71 0.21 
aPTT (s) 
 
1.01 0.90 - 1.13 0.87 1.05 0.93 - 1.17 0.45 
Operation time 
(minutes) 
 
1.02 1.00 - 1.04 0.017 1.02 1.00 - 1.03 0.065 
Anesthesia 
(Spinal) 
 
0.89 0.29 - 2.75 0.85 0.82 0.24-2.77 0.75 
EBL/kg 
 
 n.a.  1.17 1.09 - 1.26 <0.001 
aPTT = activated partial thromboplastin time, BMI = body mass index, EBL = estimated blood 
loss, LMWH = low molecular weight heparin, NSAID = non-steroidal anti-inflammatory 
drugs, PT = prothrombin time, RBC transfusion = red blood cell transfusion, SSRI = selective 
serotonin receptor inhibitor 
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Table 10. Univariate risk factor analysis in TKA patients for excessive 
bleeding and transfusion 
 Excessive bleeding 
(EBL/kg >12.7 ml/kg) 
Allogeneic RBC transfusion 
 
 
OR 95% CI p-value OR 95% CI p-value 
Age (years) 
 
1.02 0.97 - 1.08 0.45 0.99 0.92 - 1.06 0.79 
Sex (F) 
 
0.69 0.24 - 1.95 0.49 0.29 0.068 - 1.28 0.10 
BMI (kg/m2) 
 
0.81 0.69 - 0.95 0.010 0.78 0.62 - 0.98 0.034 
Weight (kg) 
 
0.96 0.92 - 1.0 0.046 0.97 0.92 - 1.02 0.26 
NSAID (No) 
 
0.94 0.26 - 3.34 0.92 0.88 0.16 - 4.68 0.88 
ASA (No) 
 
1.14 0.32 - 4.0 0.84 2.57 0.3 - 22.02 0.39 
SSRI (No) 
 
1.12 0.21 - 5.93 0.89 1.03 0.11 - 9.37 0.98 
Hemoglobin  
(g/l) 
 
1.09 1.03 - 1.16 0.001 0.91 0.84 - 0.97 0.007 
Platelet count  
(109/L) 
 
1.0 0.99 - 1.01 0.56 1.001 0.99 - 1.01 0.88 
PT (INR) 
 
0.001 0.00 - 1.03 0.051 0.036 0 - 220.4 0.46 
aPTT (s) 
 
0.91 0.78 - 1.07 0.26 1.34 1.03 - 1.74 0.028 
Operation time 
(minutes) 
 
1.00 0.98 - 1.02 0.87 1.03 1.00 - 1.06 0.034 
Anesthesia 
(Spinal) 
 
2.12 0.43 - 10.48 0.35 0.72 0.13 - 3.92 0.71 
EBL/kg 
 
 n.a.  1.020 0.88 – 1.18 0.795 
aPTT = activated partial thromboplastin time, BMI = body mass index, EBL = estimated blood 
loss, LMWH = low molecular weight heparin, NSAID = non-steroidal anti-inflammatory 
drugs, PT = prothrombin time, RBC transfusion = red blood cell transfusion, SSRI = selective 
serotonin receptor inhibitor 
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4.3 Paper III 
The three groups of patients, total hip arthroplasty (THA), total knee 
arthroplasty (TKA) and spine fusion surgery patients, differed in several 
baseline variables and coagulation parameters; age, BMI, Hb, PT, aPTT, 
fibrinogen and FXIII. Based on these findings the three surgical groups were 
analyzed separately. Preoperative fibrinogen plasma concentration and FXIII 
activity was higher in women than in men (3.4 ±0.7 vs. 3.1 ±0.7, p=0.001 and 
1.24 ±0.23 vs. 1.10 ±0.24 kIU/L, p<0.001, respectively). One THA, one TKA 
and two spine patients were reoperated, none because of bleeding 
complications.  
Information on perioperative bleeding and transfusion is presented in Table 
7, page 48. Ten (9%) of THA patients, no TKA patients and 33 (64%) spine 
patients received intraoperative cell saver autotransfusion. No THA or TKA 
patients and 49 (94%) had postoperative drainage. There was a significant 
difference in bleeding volumes between the three study groups, p<0.001. In 
spine patients, there was no direct correlation between preoperative 
fibrinogen concentration and perioperative bleeding (r=-0.15, p=0.29) but a 
fibrinogen concentration ≤2.5 g/L was associated with a significantly larger 
perioperative bleeding (2,430 (400-6,560) mL vs. 1,390 (400-7,240) mL, 
Table 11. Accordingly, the proportion of spine surgery patients with a 
bleeding volume of >2,000 mL was significantly higher in patients with low 
fibrinogen concentration (61% vs. 32%, p=0.046). No such correlation could 
be seen for THA or TKA surgery patients.  
Spine patients with fibrinogen ≤2.5 g/L were younger and had a lower BMI 
and preoperative FXIII activity while PT and aPTT were marginally longer. 
Number of segments fused and operation time did not differ significantly, 
Table 13. In a univariate analysis comparing patients with or without large 
bleeding, the only preoperative variables significantly associated with large 
bleeding were fibrinogen concentration >2.5 g/L (41% vs. 20%, p=0.046), 
and number of segments fused (5.5 (2-13) vs. 3 (2-15), p<0.001). 
There was no correlation between preoperative fibrinogen plasma 
concentration and transfusion requirements for any of the surgery groups.  
Low preoperative FXIII activity (<1.0 kIU/L) tended to correlate with large 
bleeding in spine surgery patients (p=0.055). There was no correlation 
between large bleeding and FXIII activity in THA and TKA patients. There 
was no correlation between FXIII activity and transfusion requirements in 
any of the surgery groups, Table 12.  
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Table 11. Bleeding and transfusions in THA, TKA and spine surgery patients 
with preoperative fibrinogen concentration ≤2.5 or >2.5 g/L. Median and 
range or numbers (%). 
 THA TKA Spine surgery 
Fibrinogen 
(g/L) 
≤2.5 
n = 14 
>2.5 
n = 100 
≤2.5 
n = 4 
>2.5 
n = 75 
≤2.5 
n = 18 
>2.5 
n = 34 
Bleeding  
(mL) 
 
 
1,036 
(91-2,393) 
972 
(0-4,571) 
922 
(620-1,313) 
758 
(0-1,927) 
2,430 
(400-6,560) 
1,390 
(400-7,420) 
p = 0.56 p = 0.61 p = 0.029 
Large 
bleeding  
(n) 
 
6 (6%) 2 (14%) 0 0 11 (61%) 11 (32%) 
p = 0.26  p = 0.046 
Large 
transfusion 
(n) 
 
0 4 (28%) 0 1 (1%) 11 (61%) 14 (41%) 
p = 0.45 p = 0.82 p = 0.17 
Large bleeding = >2,000 mL, large transfusion = RBC transfusion >2 units and/or transfusion 
of ≥500 mL cell saver-processed blood 
 
Table 12. Bleeding and transfusion in THA, TKA and spine surgery patients 
with FXIII concentration ≤1.0 or >1.0 kIE/L. Median and range or numbers 
(%). 
 THA TKA Spine surgery 
FXIII 
(kIU/L) 
≤1.0 
n = 28 
>1.0 
n = 86 
≤1.0 
n = 12 
>1.0 
n = 67 
≤1.0 
n = 21 
>1.0 
n = 31 
Bleeding 
(mL) 
 
 
1,011 
(34-3,191) 
964 
(0-4,571) 
626 
(368-1,393) 
782 
(0-1,927) 
2,040 
(400-7,420) 
1,380 
(400-4,100) 
p = 0.88 p = 0.11 p = 0.055 
Large  
bleeding 
(n) 
 
3 (11%) 5 (6%) 0 0 11 (52%) 11 (35%) 
p = 0.40 n.a. p = 0.26 
Large 
transfusion 
(n) 
 
2 (11%) 2 (2%) 0 1 (1 %) 10 (48%) 15 (48%) 
p = 0.23 p = 0.67 p = 0.96 
Large bleeding = >2,000 mL, large transfusion = RBC transfusion >2 units and/or transfusion 
of ≥500 mL cell saver-processed blood 
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Table 13. Pre- and intraoperative variables in spine surgery patients with 
fibrinogen concentration ≤2.5g/L or >2.5g/L. Mean and standard deviation, 
median and range or number (%). 
 Fibrinogen 
≤2.5g/L (n=18) 
Fibrinogen 
>2.5g/L (n=34) 
p-value 
 
Female gender (n) 
 
6 (33%) 13 (38%) 0.73 
Age (years) 
 
56 SD 12 65 SD 10 0.004 
BMI (kg/m2) 
 
24.7 SD 3.9 27.9 SD 4.3 0.011 
Hb (g/L)  
 
127 SD 11 122 SD 15 0.81 
Platelet count (109/L)  
 
250 SD 64 270 SD 73 0.33 
PT (INR) 
 
1.05 SD 0.09 1.12 SD 0.09 0.004 
aPTT (s) 
 
38 SD 5.9 35 SD 3.7 0.028 
Factor XIII (kIU/L) 
 
0.91 SD 0.19 1.13 SD 0.21 <0.001 
Tranexamic acid (n) 
 
8 (44%) 9 (26%) 0.19 
Number of segments (n) 
 
5 (2-13) 4 (3-15) 0.60 
Operation time (min) 
 
254 (124-516) 217 (146-362) 0.20 
Proportion of patients  
with drain (n) 
 
17(94%) 32 (94%) 0.96 
BMI = body mass index, Hb = hemoglobin level, PT = prothrombin time, aPTT = activated 
partial thromboplastin time 
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4.4 Paper IV 
Patient characteristics are presented in Table 7, page 48. There was a 
significant difference in age, gender and BMI (p<0.001) for cardiac and 
scoliosis surgery patients. Perioperative blood analysis is presented in Table 
14. 
In both cardiac and scoliosis surgery patients, supplementation with 
increasing doses of FXIII shortened clotting time (CT) and increased 
maximum clot firmness (MCF). Supplementation with FXIII in combination 
with a fixed dose of fibrinogen or platelets shortened CT and increased MCF 
more compared with only FXIII, Figure 11 and Figure 12. 
In a factorial analysis the dose-dependent effect of increasing doses of FXIII 
on CT and MCF was unaffected by the supplementation of fibrinogen or 
platelets in both cardiac and scoliosis surgery patients. In cardiac surgery 
patients there was a significant decrease in CT between the lowest and the 
highest dose of FXIII (-4.2%, 95% CI -0.4% - -8.1%, p=0.030) and a 
significant increase in MCF between the lowest and the highest dose of FXIII 
(+7.5%, 95% CI 2.2% - 12.5%, p=0.007). In scoliosis surgery patients there 
was a significant increase in MCF between the lowest and the highest dose of 
FXIII (+9.3%, 95% CI 4.2% - 14.1%, p<0.001). There was no significant 
decrease in CT between the lowest and the highest dose of FXIII (-1.5%, 
95% CI -6.6% - 3.4%, p=0.55). 
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Table 14. Perioperative blood analysis 
 Cardiac surgery 
n=9 
Scoliosis surgery 
n=10 
p-value 
between groups 
Hemoglobin (g/L) 
   Preoperative 
   Postoperative 
 
128 ± 3.3 
110 ± 4.3*** 
 
118 ± 2.8 
107 ± 3.0** 
 
0.032 
0.64 
Platelet count (×109/L) 
   Preoperative 
   Postoperative 
 
215 ± 18 
145 ± 9.7** 
 
256 ± 18 
236 ± 14 
 
0.13 
<0.001 
Fibrinogen (g/L) 
   Preoperative 
   Postoperative 
 
3.1 ± 0.16 
2.7 ± 0.20* 
 
2.4 ± 0.15 
2.0 ± 0.14** 
 
0.004 
0.011 
Factor XIII (%) 
   Preoperative 
   Postoperative 
 
90 ± 5 
78 ± 5* 
 
76 ± 4 
64 ± 4* 
 
0.035 
0.036 
EXTEM-CT (s) 
    Preoperative 
    Postoperative# 
 
45 (42-68) 
77 (60-101)** 
 
55 (41-67) 
69 (48-89)** 
 
0.079 
0.18 
FIBTEM-MCF (mm) 
    Preoperative 
    Postoperative# 
 
17 (14-26) 
12 (8-18)** 
 
12 (10-19) 
7 (6-14)** 
 
0.004 
0.020 
EXTEM-CT = EXTEM clotting time; FIBTEM-MCF = FIBTEM maximum clot firmness 
*=p<0.05, **=p<0.01, ***p<0.001, # = After dilution to maintain the same hemodilution in 
all samples. 
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Figure 7. Cardiac surgery patients. Absolute changes in EXTEM-clotting time 
(Panel A) and FIBTEM-maximum clot firmness (Panel B) after addition of 
increasing doses of Factor XIII (+20, +40 and +60%, respectively) alone or in 
combination with a fixed dose of fibrinogen or platelets.. * = p<0.05,**=p<0.01 
in comparison to baseline. 
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Figure 8. Scoliosis surgery patients. Absolute changes in EXTEM-clotting time 
(Panel A) and FIBTEM-maximum clot firmness (Panel B) after addition of 
increasing doses of Factor XIII (+20, +40 and +60%, respectively) alone or in 
combination with a fixed dose of fibrinogen or platelets. See Methods for details. 
* = p<0.05,**=p<0.01 in comparison to baseline.  
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5 DISCUSSION 
In modern orthopaedic surgery, many surgical procedures are carried out with 
minimal invasive methods, thereby minimizing bleeding and subsequently 
transfusion requirements. There are however, surgical procedures that require 
large exposures, like spine surgery, hip and knee arthroplasty surgery or 
trauma surgery. A large number of different factors can influence bleeding 
volumes and transfusion requirement and in order to minimize perioperative 
bleeding and transfusion requirements it is always important to make a plan 
to optimize the patients coagulation status and take appropriate measures. 
5.1 Bleeding and transfusion in orthopaedic 
surgery 
In Papers I and III perioperative blood loss was similar when comparing 
idiopathic scoliosis surgery, mean 1,552 mL ±1019 mL, and degenerative 
surgery patients, median 1,715 mL (range 400-7,420 mL). These numbers are 
similar with findings in other studies on bleeding in spine surgery. [241, 255] 
There was a large variation in bleeding in Paper I despite the similarity in 
surgical procedure, indicating that both patient-related and procedure-related 
factors influence perioperative blood loss. It is important to preoperatively 
identify the patients and procedures at risk of large bleeding in order 
minimize bleeding. 
In Paper II, total hip arthroplasty (THA) patients had a median visual 
perioperative bleeding of 450 mL (150-3,000 mL) and in total knee 
arthroplasty (TKA) patients 0 mL (0-600 mL). However, the calculated 
perioperative bleeding was larger and there was a significant difference 
between the two types of bleeding measurements. This can easily be 
understood in TKA patients since the surgery was done in bloodless field. 
However, a substantial hidden blood loss also occurred in THA patients and 
the reason could be that no patients in the present study received drainage 
postoperatively. The extent of occult bleeding or hidden blood loss in THA 
and TKA surgery has previously been described and should be taken into 
consideration in perioperative blood management. [145, 202] 
A study by Smorgick et al. shows hidden blood loss also occurs in spine 
surgery. [210] Paper III showed a good correlation and no significant 
difference between calculated blood loss and observed bleeding for spine 
surgery patients. A majority of the patients had postoperative drainage and 
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this regimen made it easier to assess the observed bleeding. At the same time 
drainage could increase perioperative bleeding by removing tissue pressure 
and allow for bleeding to continue. 
Previous studies show a wide range of transfusion requirements in 
arthroplasty patients, between 21-70%, with the majority of studies reporting 
numbers in the middle range. [39, 108, 193, 219] The main finding in Paper 
II was that the rate of transfusion was lower than previously reported in 
unselected patients undergoing THA or TKA surgery. In the study, 18% of 
THA and 11% of TKA patients received perioperative red blood cell (RBC) 
transfusion. These transfusion rates are similar to studies where a transfusion 
protocol was used. [30, 114, 153, 192, 211] Some studies that use 
preoperative autologous blood donation programs still describe allogeneic 
transfusion rates of 9.6% and 13% in arthroplasty patients. [30, 153] 
Transfusion requirements have been decreasing the last decades and this 
seems to be a global trend.  
The reasons behind the low transfusion rate in the present study can only be 
speculative, since indications for the transfusions given have not been 
studied. One reason could be that the patients had a normal preoperative 
hemoglobin (Hb) level which is known to decrease the risk of transfusion. 
Mean preoperative Hb levels were 136 ±12.7 g/L in THA patients and 133 
±12.3 g/L in TKA patients. Another reason could be the use of tranexamic 
acid (TXA), which is known to lower transfusion rates in orthopaedic 
surgery. 
In Papers I and III, spine surgery patients had a high transfusion rate, 37% 
in idiopathic scoliosis surgery patients and 67% in degenerative spine surgery 
patients. Similar transfusion requirements, 18-60%, can be seen in other 
studies on spine surgery patients. [33, 255] In the present studies, the higher 
transfusion rate in spine surgery, compared to THA and TKA surgery, is 
reflected in a lower perioperative bleeding. At the same time, TXA was not 
used in all spine surgery patients in Paper III compared to the patients in 
Paper I and THA and TKA surgery patients, which could also explain the 
high transfusion rate in these patients. 
There can be many reasons why there is a large difference in transfusion 
practice in general. One simple reason could be that some attending 
physicians are not aware of the risks of transfusion, thinking more about the 
risk of a postoperative low Hb level. Better knowledge about the 
disadvantages of transfusion – spread of infectious disease, transfusion 
related acute lung injury (TRALI) and immunosuppression – might reduce 
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transfusion rates. There are studies suggesting changes in attitudes towards 
lower transfusion thresholds. [95, 172] More studies need to be made on how 
both hospital staff, but also patients, perceive transfusion of blood products. 
Fast-track surgery with perioperative protocols has reduced the length of 
hospital stay in arthroplasty surgery. In order to get the patient home quicker 
it might be tempting to treat general discomfort, dizziness and tiredness after 
surgery with a RBC transfusion. Studies on fast-track THA and TKA surgery 
indicate that RBC transfusion in fact increases length of stay. [105, 107] 
Since RBC transfusion is strongly correlated with pre- and postoperative 
anemia, which also is associated with prolonged hospital stay, it is however 
difficult to determine cause and effect. [205] 
A transfusion protocol should include predefined Hb levels for transfusion as 
well as pre- and intraoperative measures to minimize bleeding and 
transfusion. Another important measure is to inform all the staff involved in 
patient care about the transfusion guidelines and about why measures are 
taken to minimize transfusions. [226] This training needs to be continuous. 
[233] 
In Paper II, the low transfusion rates were not accompanied with any high 
complication rates when compared to the literature. Since the large study on 
transfusion requirements in critical care in 1999, several other studies in the 
surgical setting have been made to identify transfusion triggers for different 
patients. [96] In 2011 a randomized, prospective study on patients with a 
history of or risk factors for cardiovascular disease, undergoing hip fracture 
surgery a transfusion trigger of Hb level <80 g/L or  <100 g/L had no impact 
on death or ability to walk independently 60 days after surgery. [45] Another 
retrospective study on patients who underwent major surgical procedures 
showed no increased risk of complications in patients with a restrictive 
transfusion trigger (Hb level <70 g/L) compared to a liberal transfusion 
trigger. [125] However, there is presently an ongoing discussion in this field. 
[66] 
Using a low Hb level as a transfusion trigger in all patients is not an end in 
itself. In a recent study examining frail elderly patients undergoing hip 
fracture surgery there was an increased 90-day mortality for nursing home 
residents in the restrictive transfusion group compared to the liberal 
transfusion group. [80] The Hb levels used in this study were higher than in 
the studies previously mentioned; <97 g/L in the restrictive group and <113 
g/L in the liberal group. In order to maintain a high acceptance for the 
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decided transfusion guidelines, a constant evaluation of the transfusion 
thresholds and their consequences in clinical practice is needed. [233]  
In patients who cannot receive RBC transfusions, for religious or medical 
reasons, blood management protocols enable safe and successful arthroplasty 
or spine surgery without the need for transfusions. [90, 91, 112] With the 
known risks following transfusion, a suggestion worth to consider ought to be 
that all patients should be treated as if they refused transfusion and 
transfusion should only be used when all other measures – preoperative, 
intraoperative and postoperative – fail to sustain sufficient oxygen delivery. 
The idiopathic scoliosis surgery patients studied in Paper I showed a 
correlation between perioperative bleeding and operation time and also with 
type of thrombosis prophylaxis; longer operation time gave a larger bleeding 
and patients with colloid prophylaxis bleed more. These risk factors for 
bleeding have been previously presented. [130, 255]  
The causality between bleeding and operation time is not clear. Operation 
time may increase because the patient is bleeding which can make it difficult 
to proceed with the surgery. On the other hand, a more complex operation 
takes longer time and can also be expected to cause more bleeding. Of course 
the operation time should not be prolonged more than is necessary for a safe 
procedure to be carried out. Preoperative planning, for instance the approach, 
the reduction method, the choice of implant, may reduce operation time and 
this could thereby, indirectly, reduce the bleeding.   
Artificial colloid infusions are known to impair hemostasis and this 
anticoagulant effect can be used as thrombosis prophylaxis. [63] Because of 
the increased bleeding risk, also described in Paper I, colloids should not 
routinely be used as thrombosis prophylaxis, especially since safer 
alternatives are now available. [71] Colloids also need to be distributed 
intravenously, which may extend the length of hospital stay. 
Paper I did not show a correlation between preoperative Hb levels and 
extensive transfusion. This correlation has been shown in previous studies in 
different surgical settings. [9, 18, 30, 82, 92, 144, 157] The reason could be 
that the patients had a sufficient preoperative Hb level, 137 ±12 g/L. Since 
there was no correlation with bleeding, another reason could be that the 
patients with low Hb bleed less and therefore did not acquire a low enough 
Hb to be subject for transfusion. On the other hand, in Paper II, low 
preoperative Hb levels were a risk factor for transfusion in both THA and 
TKA patients. The difference in results could be explained by a difference in 
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patient management and the lack of a standardized transfusion protocol. 
There are many risk factors for perioperative bleeding and transfusion 
requirements. In order to minimize bleeding and transfusion, each patient 
should be addressed according to their individual needs. 
Low body mass index (BMI) was associated with RBC transfusion in both 
idiopathic scoliosis surgery patients as well as in THA and TKA surgery 
patients in Papers I and II. The association between bleeding and 
transfusion, and BMI and obesity differs in studies. [32, 88, 110, 118] A 
patient with a low BMI has a smaller blood volume and is therefore more 
vulnerable to bleeding. Blood loss in a person with a higher BMI and a larger 
blood volume may not require transfusion but in a smaller person the same 
numeral blood loss might be enough to lower the Hb level below the 
transfusion threshold. On the other hand, surgery in obese patients could be a 
challenge, with the need for larger incisions with larger wound surfaces 
increasing the bleeding. Operation time is also known to be longer in obese 
patients compared to normal-weight patients undergoing similar surgical 
procedures. [88, 110] These factors combined could lead to an increased risk 
of large perioperative bleeding and thereby increased risk for transfusion in 
obese patients whereas factors unrelated to bleeding per se can increase the 
risk for transfusion in patients with low BMI as described above. 
It is well known that TXA reduces perioperative blood loss and RBC 
transfusion. [38, 73, 122, 225] However, TXA is not always a routine in 
major elective orthopaedic surgery, although there are convincing data 
demonstrating that a correct regimen of TXA does not lead to an increased 
risk of thromboembolic events. [38, 250] 
 
5.2 Fibrinogen; bleeding and transfusion 
Many studies have shown the correlation between preoperative fibrinogen 
concentration and perioperative bleeding in other surgical settings such as 
cardiac surgery, neurosurgery and in liver transplant surgery. [7, 11, 116, 
240] Papers I and III show a similar association in spine surgery patients. 
No such association could be seen in THA and TKA patients. The reason 
could be that THA and TKA patients did not have a sufficiently large 
perioperative bleeding for fibrinogen to reach critically low levels. The 
median perioperative bleeding for THA and TKA patients was 984 mL and 
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758 mL respectively, compared to 1,715 mL in spine surgery patients. Mean 
perioperative bleeding in scoliosis surgery patients was 1,552 mL.  
As with fibrinogen and bleeding, a correlation between preoperative 
fibrinogen plasma concentration and perioperative transfusion requirements 
has been demonstrated in different types of surgery, for instance cardiac 
surgery and liver transplant surgery. [50, 116] These are surgical procedures 
considered to be coupled with large transfusion requirements. In both Papers 
I and III there was a considerable amount of perioperative transfusions, 37% 
in scoliosis surgery patients and 67% in degenerative spine surgery patients. 
Nevertheless, a correlation was only found in idiopathic scoliosis surgery 
patients. This difference in results could be caused by the fact that fibrinogen 
concentration is only one of many factors that influence transfusion 
requirements in surgery. 
Another reason for the diverging results could be the lack of a standardized 
transfusion protocol during the study period. In Paper I, RBC transfusion 
was prescribed when the Hb level was <80 g/L. In Paper III, RBC 
transfusion was prescribed at the discretion of the attending physician. The 
recommendation today is to use transfusion protocols as a tool in prescribing 
transfusions. [86, 131]  
Even though the results in Papers I and III are not conclusive, they indicate 
that preoperative fibrinogen concentration should be one factor to consider in 
the care of these patients. In patients scheduled for surgery with a high risk of 
large bleeding, preoperative fibrinogen concentration gives more information 
on the patient’s coagulation status than prothrombin time (PT) and activated 
partial thromboplastin time (aPTT) does. [131] Adding fibrinogen 
concentration to the routine blood analysis in these patient groups could 
identify patients with low fibrinogen concentration and in the event of large 
intraoperative bleeding, supplementation with fibrinogen concentrate could 
be initiated.  
If fibrinogen concentration is not measured preoperatively, it is still 
important to bear in mind that fibrinogen is always consumed in the bleeding 
patient. In a situation with large intraoperative blood loss, the surgeon could 
be the first to observe if the patient’s coagulation is impaired and should 
notify the anesthesia staff so they can take measures. During a surgical 
procedure with large bleeding, the use of viscoelastic methods to evaluate the 
coagulation system is a fast tool for guidance on what type of blood products 
or hemostatic drugs should be given to the patient in that specific situation. 
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5.3 Factor XIII; bleeding, transfusion and 
coagulation capacity 
In Paper III no correlation could be seen between bleeding and preoperative 
FXIII activity for any of the patient groups. Studies on the effect of FXIII 
activity on perioperative bleeding have previously demonstrated diverse 
results. [7, 27, 203, 227] For instance, Blome et al. showed no correlation 
between preoperative FXIII activity and postoperative drain volume in 
cardiac surgery patients. [27] In contrast, Ternström et al. showed a 
correlation between both pre- and postoperative FXIII activity and 
perioperative blood loss in cardiac surgery patients. [227] These results in 
combination with the present study indicate a need for more research to be 
done on FXIII and perioperative bleeding and blood loss.  
It could be that FXIII activity would be more valuable as a postoperative 
marker to give an impression of how much FXIII is available to stabilize 
postoperative clot formation, as is indicated in the study by Ternström et al. 
[227] Factor XIII also influences wound healing and, if FXIII has been 
consumed during surgery and has reached critically low levels, 
supplementation might be important to improve wound healing. 
In Paper IV the main finding was that FXIII supplementation independently 
decreased clotting time (CT) and increased maximum clot firmness (MCF) in 
both cardiac and idiopathic scoliosis surgery patients in an ex vivo setting. 
The dose-dependent effect of FXIII on MCF was independent of the addition 
of fibrinogen or platelets.  
The study in Paper IV was made with clinically relevant doses of FXIII, 
fibrinogen and platelets, all of which may be used in the clinical setting to 
treat acquired coagulation disorders. [65, 131] Previous studies on ex vivo 
FXIII supplementation have used supraphysiological doses of FXIII 
concentrate and blood samples from intensive care patients or diluted 
samples from healthy volunteers. [87, 194, 208, 230] 
In Paper IV none of the cardiac surgery patients and only one of the scoliosis 
surgery patients had a postoperative FXIII activity below 0.50 kIU/L. Despite 
almost normal FXIII activity, supplementation with FXIII alone decreased 
CT and increased MCF. The effect was however limited. Compared to 
baseline CT decreased approximately 10% and MCF increased about 20% for 
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both surgery groups. The effect of fibrinogen or platelet supplementation on 
CT and MCF were markedly higher than the effect of FXIII alone. This 
finding is in line with current guidelines suggesting that FXIII 
supplementation should only be considered in patients with adequate 
fibrinogen levels or when fibrinogen supplementation is not adequate to 
restore coagulation. [65, 131] It is fibrinogen that is the critical coagulation 
factor in bleeding patients, and supplementation should focus on restoring 
fibrinogen concentration. 
In the only large scale, randomized, clinical trial with FXIII supplementation 
in cardiac surgery patients no effect was seen on bleeding and transfusion 
with recombinant FXIII. [115] When combining the results from Papers III 
and IV and also previous ex vivo studies on the effect of fibrinogen on CT 
and MCF, the effect of FXIII concentrations seems to be low compared with 
the effect of fibrinogen. [60] Consequently, the indication to use 
measurement of FXIII in clinical practice in patients undergoing orthopaedic 
surgery does not seem to be relevant in patients without coagulation 
disorders.  
5.4 Limitations 
The strength of Papers I-III is also a major limitation; the studies are made 
on consecutive patients in an everyday clinical setting without selection bias. 
In Paper III, there is a large variation in the types of spine surgery 
performed. In Papers II and III, the studied patients are restricted to hip and 
knee arthroplasty but a number of different surgeons performed the surgeries 
and different types of implants were used in the hip arthroplasty patients. 
Another limitation is that the definitions for large bleeding are based on the 
upper quartile of perioperative bleeding in Paper I and II. This makes 
comparison with other studies, using other definitions, difficult. 
Because of few studies on preoperative fibrinogen and FXIII in correlation 
with perioperative bleeding and transfusion requirements, and also the large 
variation in bleeding and transfusion requirements in the literature, power 
calculations have been difficult to make. The study population in Paper III 
might be too small to detect a correlation and also makes subgroup analysis 
difficult. 
In Papers I, II and III, a limitation is that even though different risk factors 
for large perioperative bleeding and transfusion are presented, the causality is 
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not proven. The results may be caused by other factors that covary with, for 
instance, fibrinogen. 
Paper IV examined clot formation in an ex vivo setting, and it is not clear if 
the results could be related to the clinical setting. The ex vivo model does not 
include the influence of the vascular wall and the endothelium and blood 
flow on clot formation.  
  
  
Conclusions 
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6 CONCLUSIONS 
 
• There was a correlation between preoperative fibrinogen 
plasma concentration and perioperative bleeding and red 
blood cell transfusion requirements in idiopathic scoliosis 
surgery patients. (Paper I) 
 
• Red blood cell transfusions in unselected elective total hip 
and knee arthroplasty patients were found to be lower than 
previously reported. (Paper II) 
 
• Risk factors for excessive bleeding and red blood cell 
transfusion in arthroplasty patients were low preoperative 
hemoglobin levels, low body mass index and long operation 
time. (Paper II) 
 
• There was an association between preoperative fibrinogen 
plasma concentration and perioperative bleeding but not 
with red blood cell transfusion in degenerative spine fusion 
surgery. No such correlation could be seen in hip or knee 
arthroplasty surgery patients. (Paper III) 
 
• There was no correlation between preoperative FXIII 
activity and perioperative bleeding or red blood cell 
transfusion in spine surgery, nor in hip or knee arthroplasty 
surgery. (Paper III) 
 
• Ex vivo supplementation with clinically relevant doses of 
FXIII dose-dependently improved clot formation in blood 
samples from cardiac surgery and idiopathic scoliosis 
surgery patients, both alone, and when given in combination 
with fibrinogen or platelets. (Paper IV) 
  
  
Future 
perspectives 
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7 FUTURE PERSPECTIVES 
Large perioperative bleeding, and subsequent transfusion of blood products, 
is now known to be a risk factor in surgery. Measures to minimize bleeding 
needs to be studied further, both from an efficacy and a safety perspective. 
We need to find out more about which patients are at risk of large bleeding 
during and after surgery, and focus our effort on these patients. Since the 
perioperative care of the patient involves many different categories of staff 
and also different medical specialties, communication about and consensus 
on the patient’s treatment needs to be established and reviewed.  
The role of fibrinogen, appropriate preoperative plasma concentration for 
safe surgery as well as indications for perioperative supplementation, is not 
fully established in orthopaedic surgery. Studies with greater patient numbers 
could give more information on fibrinogen and its role in perioperative 
coagulation management. It is also of interest to study fibrinogen in the 
orthopaedic trauma setting such as for hip fracture patients, who are often 
frail and need thorough perioperative care to survive both the surgical 
procedure and the postoperative rehabilitation. 
Since this is the first study on the effect of preoperative FXIII activity on 
bleeding and transfusion requirements in orthopaedic surgery more studies 
ought to be performed, preferably on larger study populations. Another 
orthopaedic aspect of FXIII is its role in bone and cartilage formation. 
Intracellular FXIII is present in chondrocytes, osteoblasts and osteocytes and 
FXIII is also involved in wound healing. Could some form of FXIII 
supplementation, systemically or locally, improve bone healing and cartilage 
regeneration? 
Bearing in mind the risks of transfusion, it is important to know when this, 
sometimes lifesaving, treatment should be given and which patients benefit 
the most. More and larger studies need to be carried out. Larger studies are 
also required to establish the relationship between transfusion and 
postoperative infection, an issue that is very important in, particularly, 
arthroplasty surgery.  
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